Vorinostat (SAHA, MK0683)

Catalog No.S1047 Synonyms: SAHA, MK0683, suberoylanilide hydroxamic acid

Molecular Weight(MW): 264.3

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Cited by 182 Publications

Cell, 2019, 176(1-2):198-212

PubMed: 30503211 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Nat Biotechnol, 2015, 10.1038/nbt.3130

PubMed: 25751058 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cell, 2014, 158(5):989-99

PubMed: 25131989 ( click the link to review the publication )

Nature, 2011, 471(7337):235-9

PubMed: 21390130 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

J Pineal Res, 2019, 66(3):e12556

PubMed: 30648757 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cancer Res, 2019, 79(7):1658-1670

PubMed: 30737231 ( click the link to review the publication )

Cancers (Basel), 2019, 11(4)

PubMed: 30935067 ( click the link to review the publication )

Clin Epigenetics, 2019, 11(1):85

PubMed: 31142371 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Pharmacol Res, 2019, 146:104281

PubMed: 31125601 ( click the link to review the publication )

Apoptosis, 2019, 24(5-6):404-413

PubMed: 30997620 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Stem Cells Dev, 2019, 28(7):438-453

PubMed: 30667343 ( click the link to review the publication )

Chem Biol Interact, 2019, 306:54-61

PubMed: 30958996 ( click the link to review the publication )

Exp Hematol, 2019, 72:60-71

PubMed: 30769020 ( click the link to review the publication )

Anticancer Res, 2019, 39(7):3579-3584

PubMed: 31262882 ( click the link to review the publication )

Exp Ther Med, 2019, 17(6):4547-4553

PubMed: 31186678 ( click the link to review the publication )
Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

J Control Release, 2018, 275:117-128

PubMed: 29474960 ( click the link to review the publication )

J Hematol Oncol, 2018, 11(1):32

PubMed: 29486795 ( click the link to review the publication )

Cancer Lett, 2018, 432:121-131

PubMed: 29890207 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Exp Cell Res, 2018, 371(1):231-237

PubMed: 30107147 ( click the link to review the publication )

Oncol Rep, 2018, 39(1):264-270

PubMed: 29115632 ( click the link to review the publication )

Ann Hematol, 2018, 97(5):839-849

PubMed: 29359239 ( click the link to review the publication )

Biochem Biophys Res Commun, 2018, 498(3):481-486

PubMed: 29505792 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(12):3139-3149

PubMed: 27986747 ( click the link to review the publication )

Haematologica, 2017, 102(4):736-745

PubMed: 27979926 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Pharm Res, 2017, 34(3):668-679

PubMed: 28101809 ( click the link to review the publication )

Cancer Med, 2017, 6(11):2673-2685

PubMed: 29024573 ( click the link to review the publication )

Int J Cell Biol, 2017, 2017:6169310

PubMed: 28321257 ( click the link to review the publication )

Connect Tissue Res, 2017, 58(1):64-75

PubMed: 27404795 ( click the link to review the publication )

Pulm Pharmacol Ther, 2017, 44:88-95

PubMed: 28323055 ( click the link to review the publication )

Am J Surg, 2017, 213(4):645-651

PubMed: 28007318 ( click the link to review the publication )

CPT Pharmacometrics Syst Pharmacol, 2017, 6(11):756-764

PubMed: 29045072 ( click the link to review the publication )

Sci Rep, 2017, 7(1):2290

PubMed: 28536458 ( click the link to review the publication )

Oncotarget, 2017, 10.18632/oncotarget.15017

PubMed: 28157715 ( click the link to review the publication )

Ann Oncol, 2016, 27(3):508-13

PubMed: 26658891 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )
Cancer Res, 2016, 76(23):7001-7011

PubMed: 27671680 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Drug Discov Today, 2016, 21(9):1553-1560

PubMed: 27371506 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(6):1364-75

PubMed: 27196750 ( click the link to review the publication )

Mol Cell Proteomics, 2016, 15(6):2076-92

PubMed: 27067055 ( click the link to review the publication )

Neuropharmacology, 2016, 107:111-121

PubMed: 26970016 ( click the link to review the publication )

Biochem Pharmacol, 2016, 102:130-140

PubMed: 26718586 ( click the link to review the publication )

Am J Pathol, 2016, 186(10):2701-8

PubMed: 27555113 ( click the link to review the publication )

J Biol Chem, 2016, 291(19):10131-47

PubMed: 27022024 ( click the link to review the publication )

Neurochem Int, 2016, 96:24-31

PubMed: 27103167 ( click the link to review the publication )

Int J Oncol, 2016, 49(6):2453-2463

PubMed: 27748897 ( click the link to review the publication )

Anal Bioanal Chem, 2016, 408(13):3547-53

PubMed: 26968571 ( click the link to review the publication )

BMC Cancer, 2016, 16:667

PubMed: 27549189 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

J Hum Genet, 2016, 10.1038/jhg.2016.61

PubMed: 27251006 ( click the link to review the publication )

Inflammation, 2016, 39(1):39-46

PubMed: 26228975 ( click the link to review the publication )

PLoS One, 2016, 11(1):e0145985

PubMed: 26726879 ( click the link to review the publication )

Onco Targets Ther, 2016, 9:6843-6855

PubMed: 27877053 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(3):692-9

PubMed: 26084206 ( click the link to review the publication )

Genet Mol Res, 2016, 15(4)

PubMed: 27819724 ( click the link to review the publication )

Oncotarget, 2016, 7(36):58142-58147

PubMed: 27494885 ( click the link to review the publication )

Sci Rep, 2016, 6:21678

PubMed: 26902929 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404396

PubMed: 25872941 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )
Clin Cancer Res, 2015, 10.1158/1078-0432.CCR-14-2701

PubMed: 25813020 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

Int J Cancer, 2015, 136(11):2717-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 356(2 Pt B):828-36

PubMed: 25449774 ( click the link to review the publication )

Cancer Lett, 2015, 366(1):32-43

PubMed: 26028172 ( click the link to review the publication )

Breast Cancer Res, 2015, 17:33

PubMed: 25888415 ( click the link to review the publication )

Acta Neuropathol Commun, 2015, 3(1):22

PubMed: 25853389 ( click the link to review the publication )

Endocr Relat Cancer, 2015, 22(5):777-92

PubMed: 26206775 ( click the link to review the publication )

Br J Haematol, 2015, 168(3):371-83

PubMed: ( click the link to review the publication )

Epigenetics, 2015, 10.1080/15592294.2015.1039216

PubMed: 25923331 ( click the link to review the publication )

Am J Cancer Res, 2015, 5(4):1337-52

PubMed: 26101701 ( click the link to review the publication )

Neuropharmacology, 2015, 99:67-78

PubMed: 26188143 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Biochem Pharmacol, 2015, 94(2):79-90

PubMed: 25600908 ( click the link to review the publication )

Biochemical Pharmacology, 2015, 94(2):79-90

PubMed: ( click the link to review the publication )

Apoptosis, 2015, 20(7):975-85

PubMed: 25835755 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(3):1829-36

PubMed: 25492871 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

BMC Cancer, 2015, 15(1):273

PubMed: 25880212 ( click the link to review the publication )

FEBS Lett, 2015, 589(10):1080-8

PubMed: 25816750 ( click the link to review the publication )

J Biotechnol, 2015, 10.1016/j.jbiotec.2015.02.029

PubMed: 25746901 ( click the link to review the publication )

Mol Med Rep, 2015, 12(3):4291-4297

PubMed: 26095064 ( click the link to review the publication )

Sci Transl Med, 2014, 6(256):256ra135

PubMed: 25273096 ( click the link to review the publication )
Nat Commun, 2014, 5:3361

PubMed: 24553445 ( click the link to review the publication )

Clin Cancer Res, 2014, 10.1158/1078-0432.CCR-14-0384

PubMed: 25355930 ( click the link to review the publication )

Int J Cancer, 2014, 135(7):1721-32

PubMed: 24615207 ( click the link to review the publication )

Diabetes, 2014, 63(9):2924-34

PubMed: 24722245 ( click the link to review the publication )

Cancer Lett, 2014, 10.1016/j.canlet.2014.10.034

PubMed: ( click the link to review the publication )

Cancer Lett, 2014, 351(1):50-8

PubMed: 24814395 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1177

PubMed: 24743732 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(12):2784-92

PubMed: 25319394 ( click the link to review the publication )

J Mol Biol, 2014, 426(20):3442-53

PubMed: 24657767 ( click the link to review the publication )

Hum Gene Ther, 2014, 25(7):599-608

PubMed: 24568341 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9918-25

PubMed: 24515107 ( click the link to review the publication )

Cancer Cell Int, 2014, 10.1186/s12935-014-0112-x

PubMed: ( click the link to review the publication )

Mol Cell Biol, 2014, 34(7):1280-9

PubMed: 24469401 ( click the link to review the publication )

Proteomics Clin Appl, 2014, 8(11-12):924-31

PubMed: 25091122 ( click the link to review the publication )

J Alzheimers Dis, 2014, 41(4):1193-205

PubMed: 24844691 ( click the link to review the publication )

Cancer Biol Ther, 2014, 15(5):578-85

PubMed: 24556916 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):373

PubMed: 24886166 ( click the link to review the publication )

FEBS Lett, 2014, 588(9):1571-9

PubMed: 24607544 ( click the link to review the publication )

Mol Med Rep, 2014, 10(5):2729-35

PubMed: 25199623 ( click the link to review the publication )

Pharmacol Res Perspect, 2014, 2(3):e00043

PubMed: 25505589 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822.

PubMed: 24986420 ( click the link to review the publication )
Cytometry A, 2014, 85(1):78-87

PubMed: 24038859 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Pharmacology Research Perspectives, 2014, 10.1002/prp2.43

PubMed: ( click the link to review the publication )

Oncotarget, 2014, 5(15):5965-77

PubMed: 25115389 ( click the link to review the publication )

Blood, 2013, 123(5):706-16

PubMed: 24319254 ( click the link to review the publication )

Nat Struct Mol Biol, 2013, 20(3):317-25

PubMed: 23377543 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 111(3):E364-73

PubMed: 24395801 ( click the link to review the publication )

PLoS Biol, 2013, 12(1):e1001758

PubMed: 24409098 ( click the link to review the publication )

Cancer Res, 2013, 73(8):2428-34

PubMed: 23382048 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Int J Cancer, 2013, 132(9):2200-8

PubMed: 23024001 ( click the link to review the publication )

Neuropsychopharmacology, 2013, 38(9):1674-84

PubMed: 23474591 ( click the link to review the publication )

Oncogene, 2013, 33(33):4265-72

PubMed: 24292675 ( click the link to review the publication )

Oncogene, 2013, 32(10):1316-29

PubMed: 22543582 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e733

PubMed: 23868066 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 160(2):188-98

PubMed: 23167276 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Biol Chem, 2013, 288(35):25593-602

PubMed: 23878197 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14400-7

PubMed: 23539624 ( click the link to review the publication )

Mol Carcinog, 2013, 52(3):218-28

PubMed: 22121107 ( click the link to review the publication )

Front Pharmacol, 2013, 4:44

PubMed: 23596417 ( click the link to review the publication )

Genes Brain Behav, 2013, 13(1):69-86

PubMed: 24286462 ( click the link to review the publication )

Cell Cycle, 2013, 12(13):2073-83

PubMed: 23759592 ( click the link to review the publication )
PLoS One, 2013, 8(1):e53766

PubMed: 23320102 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

J Exp Med, 2012, 209(1):35-50

PubMed: 22231305 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(14):3822-33

PubMed: 22623731 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Cancer Res, 2012, 72(9):2251-61

PubMed: 22422937 ( click the link to review the publication )

Cell Death Differ, 2012, 19(12):2029-39

PubMed: 22858545 ( click the link to review the publication )

Cell Death Differ, 2012, 19(8):1317-27

PubMed: 22322857 ( click the link to review the publication )

Eur J Cancer, 2012, 48(7):1096-107

PubMed: 22154545 ( click the link to review the publication )

Diabetologia, 2012, 55(9):2421-31

PubMed: 22772764 ( click the link to review the publication )

FASEB J, 2012, 26(7):3032-41

PubMed: 22459148 ( click the link to review the publication )

J Neurochem, 2012, 123 Suppl 2:108-15

PubMed: 23050648 ( click the link to review the publication )

J Leukoc Biol, 2012, 91(5):701-9

PubMed: 22028329 ( click the link to review the publication )

J Biol Chem, 2012, 287(43):36609

PubMed: 22952229 ( click the link to review the publication )

Mol Carcinog, 2012, 52(6):459-74

PubMed: 22308110 ( click the link to review the publication )

Invest New Drugs, 2012, 30(2):541-7

PubMed: 21107885 ( click the link to review the publication )

Pharm Res, 2012, 29(7):1960-76

PubMed: 22415140 ( click the link to review the publication )

Oncol Rep, 2012, 28(1):105-10

PubMed: 22484732 ( click the link to review the publication )

PLoS One, 2012, 7(9):e44265

PubMed: 22957056 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52335

PubMed: 23272238 ( click the link to review the publication )

PLoS One, 2012, 7(12):e52753

PubMed: 23300762 ( click the link to review the publication )

Chronobiol Int, 2012, 29(8):982-93

PubMed: 22891617 ( click the link to review the publication )

Biochem Biophys Res Co, 2012, 420(2):325-30

PubMed: 22425986 ( click the link to review the publication )

Pediatr Surg Int, 2012, 28(6):579-89

PubMed: 22526548 ( click the link to review the publication )
Protein Expr Purif, 2012, 86(1):45-52

PubMed: 21992606 ( click the link to review the publication )

Brain, 2011, 134(Pt 8):2408-21

PubMed: 21772061 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(9):2819-29

PubMed: 21357681 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(16):5311-21

PubMed: 21724551 ( click the link to review the publication )

Genes Dev, 2011, 25(24):2610-8

PubMed: 22016339 ( click the link to review the publication )

J Neurosci, 2011, 31(11):3990-9

PubMed: 21411642 ( click the link to review the publication )

J Transl Med, 2011, 9:37

PubMed: 21477288 ( click the link to review the publication )

Retrovirology, 2011, 2(3):411-23

PubMed: 21966324 ( click the link to review the publication )

Mol Med, 2011, 17(5-6):466-72

PubMed: 21424110 ( click the link to review the publication )

PLoS One, 2011, 6(7):e22739

PubMed: 21818379 ( click the link to review the publication )

BMC Neurosci, 2011, 12:50

PubMed: 21615950 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

J Pharmacol Exp Ther, 2010, 86(16):8765-72

PubMed: 20739454 ( click the link to review the publication )

Exp Dermatol, 2010, 19(12):1096-102

PubMed: 20629733 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

Targets

HDAC ^[1]
(Cell-free assay)

~10 nM

In vitro

Vorinostat inhibits the activities of HDAC1 and HDAC3 with IC50 of 10 nM and 20 nM, respectively. Vorinostat also results in a marked hyperacetylation of histone H4. ^[1] Vorinostat inhibits the growth of three prostate cancer cell lines LNCaP, PC-3 and TSU-Pr1 at micromolar concentrations (2.5-7.5 μM), and induces dose-dependent cell death in LNCaP cells. ^[2] Vorinostat treatment in MCF-7 cells inhibits cell proliferation at an IC50 of 0.75 μM resulting in the accumulation of cells in the G1 and G2-M phase of the cell cycle. Vorinostat also induces differentiation in the estrogen receptor-negative cell line SKBr-3 and the retinoblastoma-negative cell line MDA-468. ^[3] Vorinostat treatment at 1 μM for 8 hours or more is sufficient to irreversibly induce apoptosis of human multiple myeloma (MM) cells. The gene expression profiles of Vorinostat treated MM cells are not hallmarked by global transcriptional activation, but by coordinated transcriptional changes of specific functional groups of genes such as cytokine-induced proliferative/survival signaling cascades, oncogenes-tumor suppressor genes, regulators of apoptosis, DNA synthesis-repair and cell cycle, and proteasome-ubiquitin function. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A20	NI\HdmVMcW6jc3WgRZN{[Xl?		M4HCcFEhcA>?	NIrDOZhFVVOR	MnLwZY51cS2KRFHDNUBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xNVIh\|ryP	M{HGOFEyQTZyNEi5
Friend leukemic cell	NELj[\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUW1NEDPxE1?	NFizeJo4OiCq	NGjVcHdFVVOR	MUDJR\|UxRTBwOUmg{txO	MoHBNVIyODl7MUO=
K562	MmfWT4lv[XOnIFHzd4F6		MXy2JIg>	NYfiS2VFTE2VTx?=	MlnOTY5pcWKrdHnvckBw\iCqdX3hckBpcXO2b37lJIRm[WOndInsZZNmKCivaYj0eZJmKG:oIFjERWMyKGGwZDDISGFEOilid3n0bEBKSzVyIH;mJFAvODFizszN	MV:xNlQyQTN6MB?=
HT1080	M2PZbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnnFO\|IhcA>?	MWTEUXNQ	MkfUTWM2OD1{LkSg{txO	M3;qNFEzOjdyMUe1
H1299	Mm\UT4lv[XOnIFHzd4F6		NX32cVhDOjBibXnu	M{jtSWROW09?	Ml;OTY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JGhFSUNiZX76fY1mKHerdHigTWM2OCCxZjCwMlE6PCEQvF2=	NEOy[5cyPDV{MUSyNi=>
H1299	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGj4V4I4OiCq	MX3EUXNQ	MYLJR\|UxRTdwMkSg{txO	NVvjUndzOTR3MkG0NlI>
HeLa	M2G5UmtqdmG\|ZTDBd5NigQ>?		M1jhZlMxKG2rbh?=		MXrJcohq[mm2b4L5JINwdmOnboTyZZRqd25iYXfhbY5{fCCqaYP0c45mKGSnYXPleJlt[XOnIIfpeIghUUN3MDDv[kAxNjJ6IN88US=>	NW\jNHVWOTV4MEO5OFk>
LOX-IMVI	NI\LO3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{G3PFQ5KGh?		NW\Yeot{UUN3ME2xMlMh\|ryP	MnzpNVU4OTV2N{C=
NCI-H226	NXzL[\|FST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmPROFghcA>?		MYXJR\|UxRTJwNjFOwG0>	M2nHRlE2PzF3NEew
RXF-631L	M1[wfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIrSSFY1QCCq		Mk\pTWM2OD1{IN88US=>	MXmxOVcyPTR5MB?=
SNB-78	MnTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M4TBUVQ5KGh?		M{C3eGlEPTB;MU[g{txO	MkDiNVU4OTV2N{C=
St-4	NGnoNVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NWX1bFFuPDhiaB?=		MWnJR\|UxRTVwMjFOwG0>	MnfGNVU4OTV2N{C=
ARP1	M3u1XGZ2dmO2aX;uJGF{e2G7	MVGyJO69VQ>?	M4PUR\|YhcA>?		NE\Lc2dKdmS3Y4Tpc44hd2ZiUEKxW2FHOSCpZX7lJIV5eHKnc4Ppc44>	M1XzclE1PzN2OEC2
CEM	NESwOHVMcW6jc3WgRZN{[Xl?		MY[xJIg>	M1e4ZmROW09?	M1\CUmlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD6zN{DPxE1?	MYexOlQzODB4NB?=
HCT15	NHnVRWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MVO0PEBp		NHrqUHpIUTVyPUCuPFIh\|ryP	NEDrNXoyPjd{M{KyOy=>
NCI-H23	NV:yTog3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NU\DS5Z{PDhiaB?=		NXPC[oxPT0l3ME2wMlkzKM7:TR?=	NFrON44yPjd{M{KyOy=>
GM15850	NVu0VllPU2mwYYPlJGF{e2G7	M4fCTlIvPSEQvF2=	MX:5OkBp	NVWzOlFsTE2VTx?=	NETQTVdKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgNVQh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NXe3TFNUOTZ7MkGzOlc>
GM15850	NFOwU4FMcW6jc3WgRZN{[Xl?	M2TQU\|IvPSEQvF2=	MlLOPVYhcA>?	NFjjSFdFVVOR	MV7Jcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5iaHnzeI9v\SCKNDDsfZNqdmViNTDhZ4V1gWyjdHnvckBw\iCIWF6g[4Vv\Q>?	NVXJT4I1OTZ7MkGzOlc>
GM15850	NVX5bGlrU2mwYYPlJGF{e2G7	Mlv5Nk42KM7:TR?=	Ml;wPVYhcA>?	MlLRSG1UVw>?	MoXPTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIHjpd5RwdmViSESgcJl{cW6nIEGyJIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	MkDCNVY6OjF\|Nke=
GM15850	M3jpPGtqdmG\|ZTDBd5NigQ>?	M3;IbFIvPSEQvF2=	NULRN\|c2QTZiaB?=	M{nVSmROW09?	NECxZ41KdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIN{BtgXOrbnWgPUBi[2W2eXzheIlwdiCxZjDGXG4h\2WwZR?=	NYHjNHRoOTZ7MkGzOlc>
GM15850	M2XKXmtqdmG\|ZTDBd5NigQ>?	M1TnOlIvPSEQvF2=	M3jlPFk3KGh?	M1y1eWROW09?	M3XNOWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFi0JIx6e2mwZTC4JIFk\XS7bHH0bY9vKG:oIF\YUkBo\W6n	Mlr1NVY6OjF\|Nke=
GM15850	MkHNT4lv[XOnIFHzd4F6	MWiyMlUh\|ryP	NW\qSHdnQTZiaB?=	MlnhSG1UVw>?	NWrrNm1GUW6qaXLpeIlwdiCxZjDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFE3KGGlZYT5cIF1cW:wIH;mJGZZViCpZX7l	M3TzS\|E3QTJzM{[3
U937	MYTGeY5kfGmxbjDBd5NigQ>?	M2Sy[FUh\|ryP	MYCyOEBp	NXuwe3pQTE2VTx?=	M1zlXmNmdGxiY4njcIUh[XK{ZYP0JIJ6KGGlY4XteYxifGmxbjDheEBUN0d{L12gdIhie2V?	NFHWXHYyPzByNEexPC=>
H661	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWDoUlJ6PDhiaB?=		NXTUOHRHUUN3ME2xJO69VQ>?	NVrBNY5XOTdzNUewNFk>
U937	M1OwVWZ2dmO2aX;uJGF{e2G7	M3j5SVUh\|ryP	NIHEZ4ozPCCq	M3jTO2ROW09?	MVnJcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGGlZYT5cIF1cW:w	MnHUNVc1PDd5NUC=
U937	M1G1ZWZ2dmO2aX;uJGF{e2G7	NXnxXVdvOSEQvF2=	Ml;MNlQhcA>?	MVvEUXNQ	MYjF[oZm[3Rib36gZYxxcGFidIXieYxqdiCjY3X0fYxifGmxbh?=	M4jQVVE4PDR5N{Ww
RAW264.7	NEOwNXhHfW6ldHnvckBCe3OjeR?=	NX;Wb41TOTBizszN	M2jmRlI1cA>?	NWrDelFOf2G2ZYK=	NELB[VdKdmirYnn0bY9vKG:oIFzQV{1{fGmvdXzheIVlKFSQRnHsdIhiKHC{b3T1Z5Rqd25id3n0bEBKSzVyIH;mJFAvPzZizszN	NYe0OnFJOTd2N{e1NVg>
RAW264.7	Mmf4SpVv[3Srb36gRZN{[Xl?	NITK[mcyOCEQvF2=	MWiyOIg>	MX\3ZZRmeg>?	MmfTTY5pcWKrdHnvckBw\iCOUGOtd5RqdXWuYYTl[EBPVyCycn;keYN1cW:wIIfpeIghUUN3MDDv[kAyNjh6IN88US=>	MUKxO\|Q4PzVzOB?=
SC9	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXXiWJFwPDhiaB?=		NFr5d2FKSzVyPUCuOlA3KM7:TR?=	NHfmV40yPzVyN{KxPS=>
ST14A	NIXaR5hHfW6ldHnvckBCe3OjeR?=	NF3MV3E2KG6P	MknIO\|IhcA>?		NHeyXW1KdmO{ZXHz[UBqdiCURWPUM25TW0ZibWLORUBmgHC{ZYPzbY9v	M3XlclE4PTZ3OUmz
ST14A	NEDDToVHfW6ldHnvckBCe3OjeR?=	MWO1JI5O	MWK3NkBp		MULJcoNz\WG\|ZTDpckBGOkZzIH3SUmEh\XiycnXzd4lwdg>?	MWexO\|U3PTl7Mx?=
PANC1	NHTvW2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLHNUDPxE1?			MWDJR\|UxRTBwNEWg{txO	MoHQNVc2QDh5NES=
PANC1	MWHGeY5kfGmxbjDBd5NigQ>?	MlHNNUDPxE1?	NITyW5ozPCCq		NGHxS4hKdmO{ZXHz[UBqdiCyMkHXRWYyN0OLUEGg[4Vv\SCneIDy[ZN{cW:w	MnvSNVc2QDh5NES=
PANC1	M4nNc2Z2dmO2aX;uJGF{e2G7	MYixJO69VQ>?	NHO3RVUzPCCq		Mnj0TY5kemWjc3WgbY4heDJ5a3nwNUBo\W6nIHX4dJJme3Orb36=	MV2xO\|U5QDd2NB?=
PT45	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkXzTWM2OD12IN88US=>	MWOxO\|U5QDd2NB?=
ACHN	NF3lWXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M1jVVFIyKGh?		NVzncWZLT0l3ME2wMlY2KM7:TR?=	NX;Tc\|VtOTd4NkK2NFY>
PC3	Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmrhNlEhcA>?		MlvpS2k2OD1yLkexJO69VQ>?	NX;QemlVOTd4NkK2NFY>
A431	Mk\0R5l1d3SxeHnjJGF{e2G7		MVm3NkBp		NUDDRlBSUUN3ME20MlIh\|ryP	NE[xZpkyPzZ7MUe2Ny=>
Cal27	MkD5R5l1d3SxeHnjJGF{e2G7		M{PjNlczKGh?		MkTwTWM2OD1\|LkKg{txO	MXSxO\|Y6OTd4Mx?=
CCRF-CEM	NHf5WG1EgXSxdH;4bYMhSXO\|YYm=		M3ixSlczKGh?		NHz0U5BKSzVyPUCuPEDPxE1?	Mn\MNVc3QTF5NkO=
EOL1	NVu1XndoS3m2b4TvfIlkKEG\|c3H5		MmHVO\|IhcA>?		NXL4fpJJUUN3ME2xJO69VQ>?	MXGxO\|Y6OTd4Mx?=
Hec-1-A	NWDEe\|Z7S3m2b4TvfIlkKEG\|c3H5		M2myZVczKGh?		MWDJR\|UxRTFizszN	NWnDTotTOTd4OUG3OlM>
HeLa	M{K0e2tqdmG\|ZTDBd5NigQ>?	M2DqclExKM7:TR?=	MorGN\|AhdWmw	NVXjVFNCTE2VTx?=	MlHzTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDISGFEOSC5aYToJGlEPTBib3[gNE4xOiEQvF2=	NWfiSFM5OTd4OUG3OlM>
RKOp21	NIK2e\|ZEgXSxdH;4bYMhSXO\|YYm=		MWC3NkBp		NXfpWXE6UUN3ME2xMlc3KM7:TR?=	M4nzN\|E4PjlzN{[z
Saos2	M3;TeWN6fG:2b4jpZ{BCe3OjeR?=		M4LjWlczKGh?		Ml\WTWM2OD1{LkOg{txO	Mm\YNVc3QTF5NkO=
SK-OV-3	M3[5TGN6fG:2b4jpZ{BCe3OjeR?=		M1;iU\|czKGh?		NXjkN5V7UUN3ME2yMlIh\|ryP	MofPNVc3QTF5NkO=
U87MG	MWfDfZRwfG:6aXOgRZN{[Xl?		MmTjO\|IhcA>?		MYTJR\|UxRTFzIN88US=>	M4jaV\|E4PjlzN{[z
NUGC3	NXXmPXhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXG1JO69VQ>?	MkL5NlQhcA>?		NF;3T3lIUTVyPUKuO\|kh\|ryP	NEG5foQyPzlyNEi0Ny=>
CCD1059SK	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHnTWM2OD12Mz61JO69VQ>?	MlG2NVgzPDd3NUS=
HepG2	NIrsS\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWn6TFRbUUN3ME2wMlAxODZizszN	NYiyWpJjOTh{NEe1OVQ>
HT1080	MnjGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXLJR\|UxRTBwMECyOEDPxE1?	MnjmNVgzPDd3NUS=
SKBR3	NFH2ZYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTBwODFOwG0>	MlntNVgzPDd3NUS=
SNB78	NIDXdVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVzZN\|FwTUN3ME2xOkDPxE1?	NIT3VYcyQDJ2N{W1OC=>
SQ20B	M2\XbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIXhVFBKSzVyPUOg{txO	MWexPFI1PzV3NB?=
St4	NEjGXWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjPTnNFTUN3ME21MlIh\|ryP	NWD5OpVyOTh{NEe1OVQ>
MCF7	MXvGeY5kfGmxbjDBd5NigQ>?	MWCxNEDPxE1?	MlrNPEBp	M33YOGROW09?	MnriTY5lfWO2aX;uJI9nKHS3YoXsbY4hcHmyZYLhZ4V1gWyjdHnvci=>	NFjPelcyQDJ4OUKyOi=>
HEK293	Ml;UT4lv[XOnIFHzd4F6		NUfBOplpOSCq	MYjEUXNQ	NH75SWZKdmirYnn0bY9vKG:oIFjERWMyKHerdHigTWM2OCCxZjCwMlA{KM7:TR?=	M3HJTVE5OzB6NU[z
HEK293	NFXyTIZMcW6jc3WgRZN{[Xl?		NIf0cosyKGh?	NEDQ[3FFVVOR	M3flOGlvcGmkaYTpc44hd2ZiSFTBR\|Mhf2m2aDDJR\|UxKG:oIECuNFU4KM7:TR?=	MUSxPFMxQDV4Mx?=
G401	NWPGU2Q6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkPqO\|IhcA>?	NVy5S3FMTE2VTx?=	MXjJR\|UxRTFizszN	Mni0NVg{PzB\|N{O=
HeLa	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NULtZpRxPzJiaB?=	MYTEUXNQ	NH7TN\|VKSzVyPUCuOFYh\|ryP	NELUNnQyQDN5MEO3Ny=>
Human renal epithelial cell	MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVy3NkBp	MXTEUXNQ	M4m3[WlEPTB;MUSg{txO	MoDvNVg{PzB\|N{O=
U937	M2\heGZ2dmO2aX;uJGF{e2G7	MUi1JO69VQ>?	MlnCNlQhcA>?		MYrJcoR2[3Srb36gc4YhcGm\|dH;u[UBJPCCqeYDldoFk\XS7bHH0bY9v	MWKxPFM5OTJ\|OB?=
U937	NHfwRY1HfW6ldHnvckBCe3OjeR?=	MojkOUDPxE1?	MlTvNlQhcA>?		NXTCSIpMUW6mdXP0bY9vKG:oIHHsdIhiKHS3YoXsbY4hcHmyZYLhZ4V1gWyjdHnvci=>	NEi5THgyQDN6MUKzPC=>
U937	NYG2cFB5TnWwY4Tpc44hSXO\|YYm=	NYLtS28yPSEQvF2=	MnLBNlQhcA>?		NF;JZZNKdmS3Y4Tpc44hd2ZicEKxJIV5eHKnc4Ppc44>	NHPVfIcyQDN6MUKzPC=>
U937	MkDhSpVv[3Srb36gRZN{[Xl?	MnzmOUDPxE1?	M{\LUlI1KGh?		NG\EV5VKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m\|	M4qybFE5OzhzMkO4
U937	NFH2VXNHfW6ldHnvckBCe3OjeR?=	MXG1JO69VQ>?	NHzjeHAzPCCq		NUTWZldTUW6mdXP0bY9vKG:oIHfyZY52dG:leYTpZ{BlcW[oZYLlcpRq[XSrb36=	NX\MXnhEOTh\|OEGyN\|g>
U937	M2i0bWtqdmG\|ZTDBd5NigQ>?	MmX6OUDPxE1?	NGTZTWkzPCCq		MnHnTY5pcWKrdHnvckBw\iCqdX3hckBJTEGFMR?=	MliyNVg{QDF{M{i=
U937	NEjYXJVMcW6jc3WgRZN{[Xl?	NEnUN4c2KM7:TR?=	MlrZNlQhcA>?		NVG1R2hHUW6qaXLpeIlwdiCxZjDoeY1idiCKRFHDOC=>	MoPpNVg{QDF{M{i=
HEK-TE	NIDCS3JHfW6ldHnvckBCe3OjeR?=	MUi1JO69VQ>?	MmHjOog>	M2fGSWROW09?	M2XaOGlv[3KnYYPlJIlvKGirc4TvcoUhUDNiYXPleJlt[XSrb36=	NHnGOVkyQDR\|NEG0OC=>
HPDE6c7	NH3CSWxEgXSxdH;4bYMhSXO\|YYm=	MWi1NEDPxE1?	MnTIO\|IhcA>?	MofjSG1UVw>?	MXPJR\|UxRTFwMzFOwG0>	NHfi[oUyQDR7NES2Ny=>
Human microvascular epithelial cell	M2LwNGN6fG:2b4jpZ{BCe3OjeR?=	MXG1NEDPxE1?	MXG3NkBp	NGfHVo9FVVOR	M3nMVGlEPTB;MT6zJO69VQ>?	Mn7rNVg1QTR2NkO=
Hup T3	NV7xV3lzS3m2b4TvfIlkKEG\|c3H5	NXGxbJVHPTBizszN	NXj4V25LPzKq	M3n5RWROW09?	NYnB[XVRUUN3ME2wMlgh\|ryP	NG\Hd\|EyQDR7NES2Ny=>
Mia Paca2	MWLDfZRwfG:6aXOgRZN{[Xl?	M3S0U\|UxKM7:TR?=	MojoO\|Jp	NX;oSWFNTE2VTx?=	MkXLTWM2OD1zLkGg{txO	NFvqU\|IyQDR7NES2Ny=>
Panc 04.03	Moe5R5l1d3SxeHnjJGF{e2G7	NFn3epQ2OCEQvF2=	NI[zfVM4Omh?	M3zGVmROW09?	M{HURWlEPTB;MT6yJO69VQ>?	NEP3S3gyQDR7NES2Ny=>
SU 86.86	M3jNSmN6fG:2b4jpZ{BCe3OjeR?=	MVW1NEDPxE1?	MU[3Nog>	MoLvSG1UVw>?	NU[3emIyUUN3ME2xMlMh\|ryP	MVmxPFQ6PDR4Mx?=
HEK293	NVexXI13U2mwYYPlJGF{e2G7		MoLZN{Bp		M1XYPWlvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgTGRCSzZiZYjwdoV{e2mxbjD3bZRpKEmFNUCgc4YhOC5yMUmg{txO	M1mzZlE5PTV6Nk[5
HeLa	MlvDT4lv[XOnIFHzd4F6		MVeyJIg>		NEXrNWFKdmirYnn0bY9vKG:oIH71Z4xm[XJiSFTBR{B4cXSqIFnDOVAhd2ZiMD6wPFMh\|ryP	NHvkbYoyQDV3OE[2PS=>
RAW264.7	NVnyRnI{TnWwY4Tpc44hSXO\|YYm=	MorqNkDPxE1?	NFzjPHc{NjViaB?=	MkD0SG1UVw>?	MmTrRY51cW2jbHHybYFtKGGldHn2bZR6KGGpYXnud5QhWGyjc33v[Il2dSCoYXzjbZBienWvIHnu[oVkfGWmIIfpeIghUUN3MDDv[kAxNjFzIN88US=>	NHzme4kyQDZ2NEm2PS=>
NB4			MVO0PIg>	Mn3ZSG1UVw>?	NWmwN25NUUN3ME2wMlYh\|ryP	MkXyNVg4OjN\|NEm=
HEK293	MmrzSpVv[3Srb36gRZN{[Xl?	MknXNVAh\|ryP	MmfKNlQhcA>?	MYLEUXNQ	NXP2Z5pwSWO2aY\heIlwdiCxZjDtc5V{\SCZboSzZUB{cWewYXzpcoch\XiycnXzd4Vl	NULFUmI2OTlyMkK2O\|U>
HCT116	M2XFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWPKWoppPzKq	NUXENVExTE2VTx?=	M4rNc2lEPTB;MD6zNUDPxE1?	M3PHZVE6ODh2Mkm0
HeLa	M3\aOWtqdmG\|ZTDBd5NigQ>?	M1i5W\|Ih\|ryP	MlHQN\|AhdWmw	M2\TS2ROW09?	MXzJcohq[mm2aX;uJI9nKEiGQVOyJIlvKGi3bXHuJGhmVGFiY3XscJMhf2m2aDDJR\|UxKG:oIECuNUDPxE1?	NV[xbYl{OTlyOESyPVQ>
IGROV1	NGLhWGhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NGLuR2I4OiCq	NUDacXhkTE2VTx?=	MmTTTWM2OD1{LkKg{txO	M4rXXVE6ODh2Mkm0
IGROV1	M3:3WGtqdmG\|ZTDBd5NigQ>?	Moi0OUDPxE1?	M2rCRVI1KGh?	MVfEUXNQ	MoS2TY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KHB3MzDhZ4V1gWyjdHnvci=>	M{\hfVE6ODh2Mkm0
IGROV1	MVrLbY5ie2ViQYPzZZk>	NFTwZYQyOCEQvF2=	M4XKXlQhcA>?	M1foZ2ROW09?	NGjDfZBKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaHnzeI9v\S2KNDDhZ4V1gWyjdHnvci=>	NEnlUo0yQTB6NEK5OC=>
IGROV1	NIq4eVJMcW6jc3WgRZN{[Xl?	MX2xNEDPxE1?	MYq0JIg>	NI\nTo1FVVOR	NULoeYRoUW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDhcJBp[S22dXL1cIlvKGGlZYT5cIF1cW:w	NHKzWXgyQTB6NEK5OC=>
T24	M4rsV2tqdmG\|ZTDBd5NigQ>?		MonkN{Bp		Moi5TY5lfWO2aX;uJI9nKGirc4TvcoUhUDNiYXPleJlt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMUKg{txO	MVSxPVA5PDN7NR?=
T24	MU\LbY5ie2ViQYPzZZk>		MWmzJIg>		Moi5TY5lfWO2aX;uJI9nKGGucHjhJJR2[nWuaX6gZYNmfHmuYYTpc44hf2m2aDDFR\|UxKG:oIECuNlUh\|ryP	MYmxPVA5PDN7NR?=
HeLa	NEHsemNMcW6jc3WgRZN{[Xl?		NIDzXYkyPSCvaX6=	M1Tr[mROW09?	Ml3STY5pcWKrdHnvckBw\iCKRFHDOkBnem:vIH71Z4xm[XJiZYj0doFkfCC5aYToJGlEPTBib3[gNE4xQDV3IN88US=>	MWmxPVA6Ozh6NB?=
HeLa	NImzPIZMcW6jc3WgRZN{[Xl?		NYTaW242OTVibXnu	MYXEUXNQ	Ml7TTY5pcWKrdHnvckBw\iCKRFHDPEBnem:vIH71Z4xm[XJiZYj0doFkfCC5aYToJGlEPTBib3[gNU45PiEQvF2=	NV:0fo05OTlyOUO4PFQ>
NCI-H69	MXTDfZRwfG:6aXOgRZN{[Xl?		NGq5WWs4OiCq	NYe3XJN7TE2VTx?=	MYTJR\|UxRTJwME[g{txO	MYOxPVA6Ozh6NB?=
SKMES1	MYrDfZRwfG:6aXOgRZN{[Xl?		NUfTfmxiPzJiaB?=	M2fxemROW09?	M4DmeWlEPTB;Mj60NkDPxE1?	NV;sV\|dPOTlyOUO4PFQ>
S2	M4fzc2tqdmG\|ZTDBd5NigQ>?	NWDDTnVEOC5zLUGwJO69VQ>?	NGDJPWkyKGh?		M1K0dWlvcGmkaYTpc44hd2ZiUHzhd41w\Gm3bTDmZYxkcXCjcoXtJGhFSUNzIHX4dJJme3OnZDD3bZRpKEmFNUCgc4YhOC5yNUmg{txO	Mnn1NVk{OTd2NUC=
SHSY5Y	Mn\vT4lv[XOnIFHzd4F6	MlXvNVAh\|ryP	M13CbVQ5KGh?	NYrKR29zTE2VTx?=	MVHJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNTFOwG0>	NUPpe2oxOTl\|NESxO\|U>
SHSY5Y	MkmzR5l1d3SxeHnjJGF{e2G7	MXSxNEDPxE1?	MlLmOFghcA>?	NX\LfY03TE2VTx?=	NHXUcIRKSzVyPUKg{txO	MVexPVM1PDF5NR?=
DMS114	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NEO5RVg1QCCq		MoTPS2k2OD1{Lkmg{txO	MX:xPVQyQTJyNR?=
HBC5	NIfj[\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MnnKOFghcA>?		MonpS2k2OD1zNzFOwG0>	M3nNdFE6PDF7MkC1
SNB78	NV:zWlJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M1XESVQ5KGh?		MXrHTVUxRTF4IN88US=>	NUm5WFU3OTl2MUmyNFU>
HeLa	NHPMZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmnNO\|IhcA>?	M{TtSmROW09?	NYPsbodXUUN3ME2wMlQ3KM7:TR?=	NEn3fWYyQTR2MUi0Oi=>
BHK	MYnLbY5ie2ViQYPzZZk>	MWO1JO69VQ>?	M{j4U\|I1KGh?	MVrEUXNQ	NFXKV5lKdmirYnn0bY9vKG:oIFjERWM4KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBxdGG\|bXGgcYVu[nKjbnWgSoRmdHSjNUC4JGNHXFJicILveIVqdg>?	Mk[2NVk6PjZ5OEm=
CFBE41o-	MlXVT4lv[XOnIFHzd4F6	M2fQUlUh\|ryP	MnHuPEBp	NFyzPGxFVVOR	M{HTemlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCqeYDldoFk\XS7bHH0bY9vKG:oIHjpd5RwdmViSEO=	MnTMNVk6PjZ5OEm=
CFBE41o-	MX3LbY5ie2ViQYPzZZk>	NV3YPWJ[PSEQvF2=	NXLaOod7PCCq	MWLEUXNQ	MUPJcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcW6lcnXhd4UhcW5ibYX0ZY51KE[mZXz0ZVUxQCCFRmTSJJBzd3SnaX6gcIV3\Wx?	NETpSFkyQTl4Nke4PS=>
CFBE41o-	M4jmcWtqdmG\|ZTDBd5NigQ>?	MlzHNUDPxE1?	MUKxJIg>	MWHEUXNQ	M4jTUWlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDDSnRTKHC{b4TlbY4hdGW4ZXy=	M3jYR\|E6QTZ4N{i5
Primary bronchial epithelial cell	NXzadI1zU2mwYYPlJGF{e2G7	M3u2O\|Eh\|ryP	NEf4O\|YzPCCq	MXnEUXNQ	NFj0dXJKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnu[JVkfGmxbjDv[kBufXSjboSgSoRmdHSjNUC4JGNHXFJicILveIVqdiCjcHnjZYwhe3W{ZnHj[UBtd2OjbHn6ZZRqd25?	MVKxPVk3Pjd6OR?=
CFBE41o-	MkTET4lv[XOnIFHzd4F6	Mk\LNUDPxE1?	NX\Pdo86PSCmYYnz	M1u4NGROW09?	NYfiW5Y4UW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB{fGGkaXzpfoF1cW:wIH;mJGZl\Wy2YUWwPEBETlSUIIDyc5RmcW5?	NYezR203OTl7Nk[3PFk>
CFBE41o-	NIL1R\|JMcW6jc3WgRZN{[Xl?	M3TtS\|Eh\|ryP	NHjhVoEzPCCq	NV76WG9UTE2VTx?=	M{fSdmlvcGmkaYTpc44hd2ZiSFTBR\|ch[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gSoRmdHSjNUC4JGNHXFJicILveIVqdiC2cnHm[olkc2mwZx?=	MmTmNVk6PjZ5OEm=
CFBE41o-	NX3WVIp5U2mwYYPlJGF{e2G7	Mn\EOUDPxE1?	NFLJV2ozPCCq	MnPISG1UVw>?	Mkj4TY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDyZZRmKG:oIH3heJVz[XSrb36gc4YhS0[WUjDwdo91\WmwIITvJIl1eyCpbInjc4Zwem1?	M4DqelE6QTZ4N{i5
CFBE41o-	NGWwT\|JMcW6jc3WgRZN{[Xl?	NHPyS5k2KM7:TR?=	NH3XcJEzPCCq	NVrybnBPTE2VTx?=	NEOwWJdKdmirYnn0bY9vKG:oIFjERWM4KGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJJN1[WKrbHn0fUBw\iCIZHXseIE2ODhiQ1\UVkBxem:2ZXnu	MWGxPVk3Pjd6OR?=
CFBE41o-	M4W0fGtqdmG\|ZTDBd5NigQ>?	NWHwVJJ4PSEQvF2=	M2j3PFI1KGh?	MlT1SG1UVw>?	MnfSTY5pcWKrdHnvckBw\iCKRFHDO{Bie3Onc4Pl[EBieyClb4Ly[YN1cW:wIH;mJI12fGGwdDDG[IVtfGF3MEigR2ZVWiC2cnHm[olkc2mwZzD0c{Bk\WyuIIP1doZi[2ViYYOg[4x6[2:ob4Lt	MlLnNVk6PjZ5OEm=
Primary bronchial epithelial cell	MlnuT4lv[XOnIFHzd4F6	M2H2eVUh\|ryP	NXuwblFCOjRiaB?=	NIPvZndFVVOR	NFi1d4RKdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJI12fGGwdDDG[IVtfGF3MEigR2ZVWiCycn;0[YlvKGGyaXPhcEB{fXKoYXPlJIxw[2GuaYrheIlwdg>?	M3WydVE6QTZ4N{i5
Primary bronchial epithelial cell	NIiyXFBMcW6jc3WgRZN{[Xl?	NEWweIEyKM7:TR?=	NIKwdGM6PiCq	NI\0[3lFVVOR	NXnkSIt[UW6qaXLpeIlwdiCxZjDISGFEPyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckB{cG:{dDDjbZJkfWm2IHP1dpJmdnS\|	MmewNVk6PjZ5OEm=
BxPC3	NVfHXmtrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3vKTFczKGh?		M1:4OmlEPTB;Mj63JO69VQ>?	MVuyNFE1Ozd5OB?=
CAL27	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NH3NR5E4OiCq		NX[2WINHUUN3ME2zMlczKM7:TR?=	NWn4WGIyOjBzNEO3O\|g>
Capan1	NFy5XGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn;PO\|IhcA>?		NIXJfY9KSzVyPUeuN{DPxE1?	MUeyNFE1Ozd5OB?=
HCC827	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NUG5blRmPzJiaB?=		Mle4TWM2OD1zLkig{txO	MlvwNlAyPDN5N{i=
LNCAP	NUHqWJhpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXS3NkBp		NHrCcGVKSzVyPUCuOVgh\|ryP	NEjWS5UzODF2M{e3PC=>
NCI-H2122	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWS3NkBp		MmXaTWM2OD15LkWg{txO	NGrkZnMzODF2M{e3PC=>
NCI-H358	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIjoXYY4OiCq		MkLkTWM2OD1{LkWg{txO	NUe5UW1mOjBzNEO3O\|g>
SCC15	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Ml\tO\|IhcA>?		M1L3U2lEPTB;Mj60PUDPxE1?	MVOyNFE1Ozd5OB?=
SCC25	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NVvyOZJ[PzJiaB?=		MV;JR\|UxRTFwOUOg{txO	NXLacFlROjBzNEO3O\|g>
SKHEP1	M{XzSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NV3RSWNpPzJiaB?=		NFvpdZRKSzVyPUOuOFYh\|ryP	NIDufJozODF2M{e3PC=>
BJ	M1m1OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHTGfYYyODBizszN	MlzoOFghcA>?	MkT2SG1UVw>?	MYDHdo94fGhiaX7obYJqfGmxbjDheEAxNjB3IITvJFExOCC3TR?=	NWXvcnNOOjBzNEO4OFA>
MUF	NW\CflN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn;nNVAxKM7:TR?=	M1HSVlQ5KGh?	M{[3T2ROW09?	MojTS5Jwf3SqIHnubIljcXSrb36gZZQhOC5yNTD0c{AyODBidV2=	NFe1T4czODF2M{i0NC=>
Caco-2	NUPSTllNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIfWblgyODBizszN	NG[4NXM1QGh?	M3rORmROW09?	NF74WlBKSzVyPUiuNUDPxE1?	M4G5flIxOTR\|OESw
Caco-2	NFuxeJVMcW6jc3WgRZN{[Xl?	MXW1JO69VQ>?	NIX3SHg1KGh?	MkDMSG1UVw>?	Ml;3TY5lfWO2aX;uJI9nKEiGQVOtcYVlcWG2ZXSgbIl{fG:wZTDhZ4V1gWyjdHnvckBKSzVyIH;mJFAvODN5IN88US=>	M{PLRVIxOTR\|OESw
Caco-2	NHr4R\|BMcW6jc3WgRZN{[Xl?	NGXYSJkxNjNzNjDuUUB1dyB\|MT62JO69VQ>?	M3iwc\|QhcA>?	NXLDWZlvTE2VTx?=	NHfDbZdGgCC4aY\vJIlvcGmkaYTpc44hd2ZiaIXtZY4hUESDQ{Gge4l1cCCLQ{WwJI9nKDBwMUG5JO69VQ>?	NIT3TIIzODF2M{i0NC=>
Caco-2	MUjLbY5ie2ViQYPzZZk>	NED2ZW0xNjNzNjDuUUB1dyB\|MT62JO69VQ>?	Mk\BOEBp	MljaSG1UVw>?	MnjVSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN\|IIfpeIghUUN3MDDv[kAxNjF2NzFOwG0>	M2m4XlIxOTR\|OESw
Caco-2	M1PWcmtqdmG\|ZTDBd5NigQ>?	NGjtSW83NjN{IH7NJJRwKDZ\|MjFOwG0>	NInWTpI1KGh?	NVPjUpBwTE2VTx?=	MUTFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzVid3n0bEBKSzVyIH;mJFEzNjZizszN	NWrOb\|FOOjBzNEO4OFA>
Caco-2	NUnwZnBqU2mwYYPlJGF{e2G7	Mn7iOk4{OiCwTTD0c{A3OzJizszN	NHywV3Q1KGh?	MXzEUXNQ	MmTJSZghfmm4bzDpcohq[mm2aX;uJI9nKGi3bXHuJGhFSUN5IIfpeIghUUN3MDDv[kA1OSEQvF2=	MVqyNFE1Ozh2MB?=
Caco-2	MlK5T4lv[XOnIFHzd4F6	MkO1NE4{OTZibl2geI8hOzFwNjFOwG0>	M3;udVQhcA>?	M1HvemROW09?	MWHFfEB3cX[xIHnubIljcXSrb36gc4YhcHWvYX6gTGRCSzZ?	MmnLNlAyPDN6NEC=
HepG2	M4Pk[WtqdmG\|ZTDBd5NigQ>?	NETSWnU2KM7:TR?=	MXm2bC=>	M{DqeGROW09?	MWLJcoR2[3Srb36gc4YhUESDQz3t[YRq[XSnZDDobZN1d26nIHHj[ZR6dGG2aX;u	NX\FXoxuOjBzNEO4OFA>
HepG2	M3K0[mtqdmG\|ZTDBd5NigQ>?	NUezVJQ1PSEQvF2=	NXnyZ3hbPmh?	Mnn1SG1UVw>?	M2H1Wmlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIhqe3SxbnWgbJlx\XKjY3X0fYxifGmxbh?=	MX[yNFE1Ozh2MB?=
HepG2	NFnh[GxMcW6jc3WgRZN{[Xl?	MUW1JO69VQ>?	MYC2bC=>	NHW3UFBFVVOR	M3Phemlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJIFteGijLYT1ZpVtcW5iYXPleJlt[XSrb36=	NFzCfGczODF2M{i0NC=>
HepG2	NX\pO2NuU2mwYYPlJGF{e2G7	M3jScFUh\|ryP	M4HWclZp	MmfUSG1UVw>?	M3;NcWlv\HWldHnvckBw\iCKRFHDMY1m\GmjdHXkJGg{N0h2IHjpd5RwdmViYXPleJlt[XSrb36=	MU[yNFE1Ozh2MB?=
COLO205	NFzXZnhMcW6jc3WgRZN{[Xl?	MlXJNVAh\|ryP	NHKyOHEzPCCq	NH3BVI1FVVOR	MULJcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizJIFk\XS7bHH0bY9vKHerdHigTWM2OCCxZjCyMlIh\|ryP	Mn24NlA1PTF\|N{i=
SCC4	NHG0XZBMcW6jc3WgRZN{[Xl?	NX;SO4xnOSEQvF2=	MkHLNlRp		MoLFTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGmwY4LlZZNmKGmwIIT1ZpVtcW5iYXPleJlt[XSrb36=	M2Kw[FIxPDV{MkK1
SCC4	M{PFdmtqdmG\|ZTDBd5NigQ>?	NX\XS5E3OSEQvF2=	M2PyfFI1cA>?		M1PVdmlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIHHj[ZR6dGG2aX;u	MUOyNFQ2OjJ{NR?=
SCC4	MXrGeY5kfGmxbjDBd5NigQ>?	MVixJO69VQ>?	MoDTOUBucW5?		MmrsRYdwdmm\|dDDhZ5Rqfmm2eTDheEBXTFJiYYPz[ZN{\WRiYYOgbY5lfWO2aX;uJI9nKEO\UEK0JIdmdmViZYjwdoV{e2mxbh?=	NF33W4kzODR3MkKyOS=>
NB4	MkT3SpVv[3Srb36gRZN{[Xl?	NWHhNnRxPSEQvF2=	MUKyOEBp	NXXzeWl1TE2VTx?=	MVTD[YxtKGO7Y3zlJIFzemW\|dDDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCjY3P1cZVt[XSrb36gZZQheHKnLVexJJBp[XOn	NX3wfVlMOjB2OUG0OFA>
NB4	MkTwT4lv[XOnIFHzd4F6	NFPYNVc2KM7:TR?=	NFr5RnIzPCCq	MmX3SG1UVw>?	NIjkeo1KdmirYnn0bY9vKG:oIFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gZYNmfHmuYYTlJJR2[nWuaX6gcIV3\Wx?	NVPMSI5kOjB2OUG0OFA>
NB4	MV\GeY5kfGmxbjDBd5NigQ>?	NVrpOFNQPSEQvF2=	NWT2T4FXOjRiaB?=	MYPEUXNQ	Mn;XTY5lfWO2aX;uJI9nKHB{MWfBSlEwS0mSMTDlfJBz\XO\|aX;u	M4npV\|IxPDlzNESw
NB4	MmLhT4lv[XOnIFHzd4F6	Ml;rOUDPxE1?	MofBNlQhcA>?	M1PkVWROW09?	M{C2NGlvcGmkaYTpc44hd2ZiSFTBR{Bie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDobZN1d26nIFizJIFk\XS7bHH0bY9v	M3S0fFIxPDlzNESw
NUGC3	M4DOVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUPHTVUxRTJwOUSg{txO	M2DTPFIxQDVyOUex
A549	MVLGeY5kfGmxbjDBd5NigQ>?	MVm1JO69VQ>?	NGnhWHQ{KGh?	NX7KS3o1TE2VTx?=	Mn:3TY5lfWO2aX;uJI9nKGG3dH;wbIFogSCrbjDoeY1idiCDNUS5JINmdGy\|IHHzd4V{e2WmIHHzJIlv[3KnYYPlJIlvKEyFM1nJ	M3PHSVIxQDV3MkC4
HUT78	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MXS3NkBp	M2rYVWROW09?	MVXHTVUxRTBwMzFOwG0>	MlzvNlA5QDR{MEi=
U937	M4rmOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NUTocW5vPzJiaB?=	M1nKPGROW09?	Ml:yS2k2OD1yLkO5JO69VQ>?	M{TBfVIxQDh2MkC4
A431	NHzhXJNEgXSxdH;4bYMhSXO\|YYm=		MUi3NkBp		M37NU2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE1OzFiY3XscJMhd3[ncnX4dJJme3OrbnegSWdHWiC5aYToJGlEPTBib3[gOE4zKM7:TR?=	Mn\WNlExQDB4Mkm=
A549	MVzDfZRwfG:6aXOgRZN{[Xl?		Mn;PO\|IhcA>?		MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJI93\XKneIDy[ZN{cW6pIFjERWMhf2m2aDDJR\|UxKG:oIEGuPEDPxE1?	MVSyNVA5ODZ{OR?=
CAL27	Mn\RR5l1d3SxeHnjJGF{e2G7		MVK3NkBp		NUDmepRuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hS0GOMkegZ4VtdHNib4\ldoV5eHKnc4PpcochTUeIUjD3bZRpKEmFNUCgc4YhOy5{IN88US=>	MnXsNlExQDB4Mkm=
HeLa	NF64SnVEgXSxdH;4bYMhSXO\|YYm=		MYG3NkBp		NHPQd3hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\UyjIHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhFSUNid3n0bEBKSzVyIH;mJFEvPSEQvF2=	NUKxZpJMOjFyOEC2Nlk>
Sf21	NUTlfWIyU2mwYYPlJGF{e2G7		M1r1XFMhcA>?		NXjTW3IzUW6qaXLpeIlwdiCxZjDGcIFoKHSjZ3fl[EBpfW2jbjDy[YNwdWKrbnHueEBJTEGFODDlfJBz\XO\|ZXSge4l1cCCLQ{WwJI9nKDFwMjFOwG0>	MnTxNlExQDB4Mkm=
SKBR3	MU\DfZRwfG:6aXOgRZN{[Xl?		MYO3NkBp		M33aNGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMSlJ\|IHPlcIx{KG:4ZYLlfJBz\XO\|aX7nJGhGWjJid3n0bEBKSzVyIH;mJFIvPiEQvF2=	MW[yNVA5ODZ{OR?=
SKOV3	MlG4R5l1d3SxeHnjJGF{e2G7		M3:5PVczKGh?		MmXhR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2tQXjNiY3XscJMhd3[ncnX4dJJme3OrbnegTGVTOiC5aYToJGlEPTBib3[gNk4zKM7:TR?=	NIPBd40zOTB6ME[yPS=>
COR-L23	NVzKS4VtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYHUWI95OTBizszN	M2HFUVczKGh?	NY\3Rnk6TE2VTx?=	M3vVZmdKPTB;MT6xJO69VQ>?	MnHoNlExQDB4NEe=
DU145	MoP5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NW\BdJBbOTBizszN	MVO3NkBp	M{LLO2ROW09?	MWPHTVUxRTFwMEWg{txO	MXqyNVA5ODZ2Nx?=
LoVo	NFSzVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGjsOmIyOCEQvF2=	M1nTRVczKGh?	M1\HRmROW09?	NGK3clFIUTVyPUGuO{DPxE1?	NX7POnJzOjFyOEC2OFc>
MCR5-SV2	NUPiU5ZET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoL2NVAh\|ryP	M4LvXVczKGh?	MVLEUXNQ	M{DkN2dKPTB;Mj6xJO69VQ>?	Ml3YNlExQDB4NEe=
HCT116	M{fXZmtqdmG\|ZTDBd5NigQ>?	NVi2bZN6OzBizszN	NHvUbGw{OCCq	NX;pTWk5TE2VTx?=	NYPiN\|hnUW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDpcoR2[3Srb36gc4Yh[WyyaHGteJVjfWyrbjDhZ4V1gWyjdHnvci=>	NEfHZW8zOTB6ME[0Oy=>
HCT116	MXLLbY5ie2ViQYPzZZk>	NX;yZpJMOzBizszN	NV7IW4J{OzBiaB?=	NULRXIhjTE2VTx?=	MVvJcohq[mm2aX;uJI9nKEiGQVOxJIF{e2W\|c3XkJIF{KGmwZIXjeIlwdiCxZjDobZN1d26nIFizT\|kh[WOndInsZZRqd25?	M{exNVIyODhyNkS3
U937	NYPzVnpVU2mwYYPlJGF{e2G7	NXfNc5F{PSEQvF2=	M3O0bFI1KGh?	NUnxNnJ{TE2VTx?=	M{HhemlvcGmkaYTpc44hd2ZiaHnzeI9v\SCjY3X0fYx1emGwc3\ldoF{\SCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDv[kBi[2W2eXzheIlwdiCxZjDobZN1d26nIFizJIF1KEt7	NIP1b5YzOTJ7MkS5Ni=>
U937	NYDwelNOU2mwYYPlJGF{e2G7	M3iwclUh\|ryP	M1HvelI1KGh?	NYTBem9ETE2VTx?=	NX3ET\|ZKUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGGlZYT5cIF1cW:wIH;mJIhqe3SxbnWgTFMh[XRiS{G4	MkC1NlEzQTJ2OUK=
U937	NHrsbm1McW6jc3WgRZN{[Xl?	M4W5VVUh\|ryP	MXOyOEBp	MV3EUXNQ	NIn2W2JKdmirYnn0bY9vKG:oIHjpd5RwdmViYXPleJltfHKjboPm[ZJie2ViYYPz[ZN{\WRiYYOgbY5kemWjc3Wgc4YheGGwLXHj[ZR6dGG2ZXSgbIl{fG:wZTDIOEBt\X[nbB?=	NIju[IkzOTJ7MkS5Ni=>
U937	M3vGSWtqdmG\|ZTDBd5NigQ>?	MUm1JO69VQ>?	NHrJcHAyPSCvaX6=	M4LrcmROW09?	NXXSRmRnUW6qaXLpeIlwdiCxZjDobZN1d26nIHHj[ZR6dHS{YX7z[oVz[XOnIHHzd4V{e2WmIHHzJIlv[3KnYYPlJI9nKGirc4TvcoUhUDNiYXPleJlt[XSrb36gcIV3\Wx?	MUWyNVI6OjR7Mh?=
A2780	M1zjUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmjOPVYhcA>?	NH3mS49FVVOR	M4fkTGlEPTB;MT62NkDPxE1?	NUez[oc1OjF4M{S0N\|A>
COLO205	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1vydlk3KGh?	Mnf3SG1UVw>?	MmPiTWM2OD1{LkGyJO69VQ>?	MYCyNVY{PDR\|MB?=
Hep3B	M{[xbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MWS0PEBp	NF\2UWFFVVOR	MnLYS2k2OD1zLkKxJO69VQ>?	NH;kT4UzOTdzMkG0Oi=>
GM11272	M2DqR2Z2dmO2aX;uJGF{e2G7	NEnQWpQyODBibl2=	NHHQcWo4OiCq	NUXF[4pjTE2VTx?=	NHWybpFT\WGldHn2ZZRqd25ib3[gUYVEeDJibYX0ZY51KGW6cILld5Nqd25iYYSgNVAhfG9iMUCwJI5O	M{jlW\|IyQDRyN{G2
CFBE41o	MXfLbY5ie2ViQYPzZZk>	NFzEZZE2KM7:TR?=		MX\EUXNQ	M1fXWGRwf25icnXneYxifGmxbjDv[kBJTEGFNzDheEAxNjJidH:gOUB2VQ>?	M3;YV\|IyQTh2OUW4
CFBE41o	M2f4NGZ2dmO2aX;uJGF{e2G7	M1XOXlEh\|ryP	MkP3NlQhcA>?	MlTmSG1UVw>?	NV7YN2FZWmW\|dH;yZZRqd25ib3[gR2ZVWiCmZXz0ZWY2ODhibYX0ZY51KHS{YX\mbYNscW6pIITvJINmdGxic4Xy[oFk\SCjczDncJlkd2[xcn3z	NGHhXHYzOTl6NEm1PC=>
DU145	MUTLbY5ie2ViQYPzZZk>	NVPEUYVkOi53IN88US=>	MVKyOEBp	MlTZSG1UVw>?	MlflTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KHWycnXneYxifGmxbjDv[kBxOjG5YX[xJJBzd3SnaX6g[ZhxemW\|c3nvci=>	NYDZWoRUOjJ{NkCxOlY>
DU145	Mnq1T4lv[XOnIFHzd4F6	MYq1JO69VQ>?	MmnKNlQhcA>?	NUjKVY9uTE2VTx?=	MX;Jcohq[mm2aX;uJI9nKEiGQVOgZZN{\XO\|ZXSgZZMhcGm\|dH;u[UBJPCCjY3X0fYxifGmxbh?=	NFHmZoYzOjJ4MEG2Oi=>
DU145	M4DCUmtqdmG\|ZTDBd5NigQ>?	NITF[4E2KM7:TR?=	NY\4fpFXOjRiaB?=	NGfSbVNFVVOR	MlHDTY5pcWKrdHnvckBw\iCKRFHDJIF{e2W\|c3XkJIF{KGirc4TvcoUhUDNiaInw[ZJi[2W2eXzheIlwdg>?	NXy4XZpsOjJ{NkCxOlY>
786-0	NU\KfHdxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWP1[npjPi5{IN88US=>	MWq3NkBp	MWTEUXNQ	MV;HTVUxRTNwMjFOwG0>	M3yzS\|IzPDN3Nk[5
A498	NH;OPYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXPl[HlQPi5{IN88US=>	MWi3NkBp	NHz3cVJFVVOR	NIj5ZmFIUTVyPUGuOkDPxE1?	M{S1b\|IzPDN3Nk[5
A549/ATCC	M1v5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYLXO3NGPi5{IN88US=>	M2jT[\|czKGh?	M2rjNWROW09?	MlPkS2k2OD1zLk[g{txO	MnS4NlI1OzV4Nkm=
ACHN	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnv4Ok4zKM7:TR?=	MVK3NkBp	M1XITGROW09?	NVz3c3d3T0l3ME2xMlMh\|ryP	MXOyNlQ{PTZ4OR?=
BT549	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVexZWgxPi5{IN88US=>	MUC3NkBp	Mlq4SG1UVw>?	NIqzOpVIUTVyPUGuN{DPxE1?	MV[yNlQ{PTZ4OR?=
EKVX	M3\lUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NG\HT2o3NjJizszN	NE\Fcog4OiCq	Mn\zSG1UVw>?	MV;HTVUxRTFwMzFOwG0>	NFnSe\|EzOjR\|NU[2PS=>
HCT15	M1fOb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYm2MlIh\|ryP	NFfpUYs4OiCq	M3LoVWROW09?	NGrvOVhIUTVyPUKuOUDPxE1?	MlvlNlI1OzV4Nkm=
HOP92	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGfhS3g3NjJizszN	NFrJZpA4OiCq	MUnEUXNQ	NGTYToZIUTVyPUSg{txO	MXqyNlQ{PTZ4OR?=
IGROV1	MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoPHOk4zKM7:TR?=	MWm3NkBp	M1m1TGROW09?	NW\xVJYzT0l3ME2xMlMh\|ryP	NVTTenRKOjJ2M{W2Olk>
LOXIMVI	NV:3R\|ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvSd2g3NjJizszN	MVS3NkBp	MoT3SG1UVw>?	NHnSO\|RIUTVyPUGg{txO	NULjVHdbOjJ2M{W2Olk>
M14	M3[2eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVW2MlIh\|ryP	NF64XG04OiCq	NV3NPWl4TE2VTx?=	NX\VRVM2T0l3ME2xMlMh\|ryP	NIj2OnozOjR\|NU[2PS=>
MALME-3M	Mon0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWPzT2dtPi5{IN88US=>	MoGxO\|IhcA>?	M2TjWmROW09?	NXLDVIlOT0l3ME2wMlMzKM7:TR?=	NV;mO4l4OjJ2M{W2Olk>
MCF10A	NIDPR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVS2MlIh\|ryP	NFTzVWs1QCCq	M{\rUmROW09?	MXvHTVUxRTlwNjFOwG0>	NWjifFQzOjJ2M{W2Olk>
MDA-MB-435	M4TzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnrZOk4zKM7:TR?=	MlK0O\|IhcA>?	NYCxenRGTE2VTx?=	M3X5WWdKPTB;MD61JO69VQ>?	M4HRNVIzPDN3Nk[5
MDA-MB-468	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnG[4k3NjJizszN	MW[3NkBp	MmfYSG1UVw>?	NIDs[YRIUTVyPUCuOlMh\|ryP	M1PRdVIzPDN3Nk[5
MOLT4	MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mlu2Ok4zKM7:TR?=	NYrNSIs6PzJiaB?=	MYjEUXNQ	M3nM[mdKPTB;MD60JO69VQ>?	M17GSFIzPDN3Nk[5
NCI-ADR-RES	MoS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlfPOk4zKM7:TR?=	NG\jWGY4OiCq	MoLRSG1UVw>?	MYrHTVUxRTBwMU[g{txO	NXfVR3B7OjJ2M{W2Olk>
NCI-H23	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGO4PHQ3NjJizszN	NEjMNmY4OiCq	NHPjdmJFVVOR	NXnUV4NST0l3ME2xJO69VQ>?	MWKyNlQ{PTZ4OR?=
NCI-H322M	NHXOR4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrYbnI3NjJizszN	M2DDc\|czKGh?	MknNSG1UVw>?	Mln3S2k2OD1yLke5JO69VQ>?	MVGyNlQ{PTZ4OR?=
NCI-H460	M4fYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Ml;wOk4zKM7:TR?=	MXe3NkBp	NXjTV\|JxTE2VTx?=	M332WGdKPTB;MD63PUDPxE1?	M{\mflIzPDN3Nk[5
NCI-H522	MoflS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnj3Ok4zKM7:TR?=	MkS5O\|IhcA>?	MXHEUXNQ	MX7HTVUxRTBwNTFOwG0>	MWeyNlQ{PTZ4OR?=
OVCAR3	NEfiWGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmHCOk4zKM7:TR?=	Ml70O\|IhcA>?	M1mwSGROW09?	MmTLS2k2OD1zLkOg{txO	M3LJcVIzPDN3Nk[5
OVCAR4	NHH1R5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVK2MlIh\|ryP	NYHRNWVkPzJiaB?=	M3\CUWROW09?	NWnNVodLT0l3ME20JO69VQ>?	MlS3NlI1OzV4Nkm=
OVCAR5	NXjxSXRJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoTzOk4zKM7:TR?=	NIPGeXo4OiCq	M2fFV2ROW09?	NGDq[pFIUTVyPUCuO\|kh\|ryP	M4DSN\|IzPDN3Nk[5
OVCAR8	MnziS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkC2Ok4zKM7:TR?=	M4PSRVczKGh?	NGPoflBFVVOR	MYfHTVUxRTBwNTFOwG0>	NYnmb2kzOjJ2M{W2Olk>
RXF393	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoDDOk4zKM7:TR?=	MofwO\|IhcA>?	NGX2TnFFVVOR	NEG4V\|dIUTVyPUGuN{DPxE1?	NXW4OItjOjJ2M{W2Olk>
SF268	NH;nWG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYi2MlIh\|ryP	M{\2b\|czKGh?	NEe2XW1FVVOR	MoXNS2k2OD1zLk[g{txO	NF;iSXgzOjR\|NU[2PS=>
SF295	M4XIdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zjcVYvOiEQvF2=	NEXyNYM4OiCq	M3TpcGROW09?	MU\HTVUxRTFwNjFOwG0>	M{TQVlIzPDN3Nk[5
SF539	NVz0d5hOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MU[2MlIh\|ryP	NHfMPHo4OiCq	NViwNnloTE2VTx?=	MoDzS2k2OD1{IN88US=>	NEDNTZYzOjR\|NU[2PS=>
SK-MEL-2	NYj3dpNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\BOk4zKM7:TR?=	MmXPO\|IhcA>?	NV7wOIxpTE2VTx?=	NF2ze21IUTVyPUGuN{DPxE1?	M{jN[VIzPDN3Nk[5
SK-MEL-28	M2rJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEnH[mY3NjJizszN	NV;z[YFmPzJiaB?=	MoHaSG1UVw>?	MV7HTVUxRTFizszN	MoK2NlI1OzV4Nkm=
SK-MEL-5	MkS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXi5SoJWPi5{IN88US=>	M{DGelczKGh?	MkfqSG1UVw>?	MkX1S2k2OD1yLk[zJO69VQ>?	NYeyfHQ1OjJ2M{W2Olk>
SKOV3	NYGxNI86T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHY[4k3NjJizszN	NX7NZm41PzJiaB?=	M3y0SGROW09?	MXXHTVUxRTFizszN	MU[yNlQ{PTZ4OR?=
SN12C	Mlv4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoL4Ok4zKM7:TR?=	MnnKO\|IhcA>?	MVLEUXNQ	M1\1V2dKPTB;MjFOwG0>	NYnkemdLOjJ2M{W2Olk>
SNB19	NEjpc5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NG\XU3E3NjJizszN	NGDKUZY4OiCq	MojqSG1UVw>?	MmnIS2k2OD1yLk[zJO69VQ>?	M2\CUlIzPDN3Nk[5
SNB75	Ml[yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlKwOk4zKM7:TR?=	MXK3NkBp	MYXEUXNQ	NYrXb\|hbT0l3ME2wMlc6KM7:TR?=	NFzCR5MzOjR\|NU[2PS=>
SR	NX\lOJNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2nObVYvOiEQvF2=	M13aUlczKGh?	NX3QeJM3TE2VTx?=	MX;HTVUxRTBwNDFOwG0>	M1zxdlIzPDN3Nk[5
T47D	NX;UUotzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1\rV\|YvOiEQvF2=	Mk\rO\|IhcA>?	MmjRSG1UVw>?	MlPBS2k2OD1yLkWg{txO	MXqyNlQ{PTZ4OR?=
TK10	MlPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTnbnM3NjJizszN	M{eyV\|czKGh?	MWrEUXNQ	NWDpXVlqT0l3ME2wMlY{KM7:TR?=	MWKyNlQ{PTZ4OR?=
UACC257	Mof1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVruNGR4Pi5{IN88US=>	NULCN2lVPzJiaB?=	MUTEUXNQ	NGK3PGJIUTVyPUCuOUDPxE1?	M2XSR\|IzPDN3Nk[5
UACC62	NEnkRmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PR[FYvOiEQvF2=	MV[3NkBp	M{PGVmROW09?	MWDHTVUxRTBwNDFOwG0>	NFTLdWMzOjR\|NU[2PS=>
UO31	M1vaSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGm5T\|M3NjJizszN	MliyO\|IhcA>?	NYrjRY9nTE2VTx?=	NH3ZVoRIUTVyPUCuOUDPxE1?	NGnPZ5YzOjR\|NU[2PS=>
Hep3B	Mnj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV[0PEBp	MWHEUXNQ	NVPzdHJnT0l3ME2wMlY6KM7:TR?=	NV7Ld5ltOjJ2M{m4OlM>
BE(2)-C	NIrxOY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXG3NkBp	NV62PJJKTE2VTx?=	MVvJR\|cxRTJizszN	MVqyNlk{OjNzNh?=
Bel7402	M3\oV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUe3NkBp	M{LqdGROW09?	NF;YfZdIUTlyPUG3JO69VQ>?	M4rL[\|I{ODZzM{e2
Bel7404	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NIDGVVE4OiCq	NVX1VmVSTE2VTx?=	MYfHTVkxRTF6IN88US=>	MX:yN\|A3OTN5Nh?=
BGC823	MlvIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVu3NkBp	M3y4OWROW09?	MofkS2k6OD15LkWg{txO	NFPCcFUzOzB4MUO3Oi=>
MGC803	M3vJSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MVi3NkBp	M4\o[2ROW09?	Mn;jS2k6OD1zMD64JO69VQ>?	NVrFXZR{OjNyNkGzO\|Y>
SGC7901	M33KTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MnjoO\|IhcA>?	MWDEUXNQ	MW\HTVkxRTlwNDFOwG0>	MofGNlMxPjF\|N{[=
SKHEP1	MnGyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXW3NkBp	NU\mU5RMTE2VTx?=	MknkS2k6OD1zNzFOwG0>	NHPCT5czOzB4MUO3Oi=>
SMMC7721	NHyzNY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MorBO\|IhcA>?	MYPEUXNQ	NYfzZlhGT0l7ME2yNEDPxE1?	NVfV[I1TOjNyNkGzO\|Y>
NUGC3	M175dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWGxNEDPxE1?			NHHKZZBIUT1{Lkm0JO69VQ>?	M2j5UVI{OTZ\|M{Oy
A2780 CisR	NIOyXGNMcW6jc3WgRZN{[Xl?		NUf4cVZYOThiaB?=		M4PPNmlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD60OEDPxE1?	MnzLNlMzPTJ4MEO=
CAL27 sens	NGL1N49McW6jc3WgRZN{[Xl?		M3\OR\|E5KGh?		NF[xPHhKdmirYnn0bY9vKG:oIFjERWMhf2m2aDDJR\|UxKG:oIECuN\|Yh\|ryP	MUeyN\|I2OjZyMx?=
CAL27 CisR	NY[0fplNU2mwYYPlJGF{e2G7		M2PVRVE5KGh?		MXXJcohq[mm2aX;uJI9nKEiGQVOge4l1cCCLQ{WwJI9nKDBwNkGg{txO	MUGyN\|I2OjZyMx?=
KYSE-510 CisR	MoPLT4lv[XOnIFHzd4F6		M4jjelE5KGh?		NXGwTZJYUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlU6KM7:TR?=	MYmyN\|I2OjZyMx?=
KYSE-510 sens	NXPENm5GU2mwYYPlJGF{e2G7		M1\NVVE5KGh?		M4LBemlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD63JO69VQ>?	NEHOV\|EzOzJ3Mk[wNy=>
MDA-MB-231 sens	M1PhZ2tqdmG\|ZTDBd5NigQ>?		MV[xPEBp		NVrSfWpnUW6qaXLpeIlwdiCxZjDISGFEKHerdHigTWM2OCCxZjCwMlYyKM7:TR?=	MmWxNlMzPTJ4MEO=
MDA-MB-231 CisR	NF7uNoZMcW6jc3WgRZN{[Xl?		MWmxPEBp		M3jFfWlvcGmkaYTpc44hd2ZiSFTBR{B4cXSqIFnDOVAhd2ZiMD62NUDPxE1?	M{TONVI{OjV{NkCz
ES2	M1nZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVvrPFlrPDhiaB?=	MVnEUXNQ	NV7zS3lKUUN3ME2xNk44KM7:TR?=	M3GxVFI{PDl\|NES5
MDA-MB-231	MWXLbY5ie2ViQYPzZZk>	MoX2NVAh\|ryP	NI\vfHE{OCCvaX6=	NHXCcWVFVVOR	NUi5bWxvUW6qaXLpeIlwdiCxZjDISGFEOmF?	NVXzSXZxOjN2OUO0OFk>
MDA-MB-231	Mn\xT4lv[XOnIFHzd4F6	MkXFNUDPxE1?	MWeyOEBp	NV75eVJTTE2VTx?=	NV\veG5sUW6qaXLpeIlwdiCxZjDISGFEPiCjc4Pld5Nm\CCjczDhZ4V1gWyjdHnvckBt\X[nbIOgc4YhfHWkdXzpci=>	Mme1NlM1QTN2NEm=
HS68	NH35dIJEgXSxdH;4bYMhSXO\|YYm=	NYXFOlBUOTBizszN	MmO0O\|IhcA>?	M3uyemROW09?	MV7JR\|UxRTRwNjFOwG0>	MkLNNlM2PzB3NEK=
MEF	NH7WW2dEgXSxdH;4bYMhSXO\|YYm=	MlX2NVAh\|ryP	NWDDOFZqPzJiaB?=	MmXESG1UVw>?	NUPOboRpUUN3ME20MlQh\|ryP	MlXhNlM2PzB3NEK=
BGC823	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			MorNSG1UVw>?	M2HaWGdKPTB;Mz6wPUDPxE1?	NXu0[ZEyOjN4MEG3NFY>
High5	MkfYT4lv[XOnIFHzd4F6		MWWyOEBp		NF\wOllKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IFjERWM3KHerdHigTWM2OCCxZjCwMlA6KM7:TR?=	MVOyN\|YxOjV{Mx?=
High5	M1LCWWtqdmG\|ZTDBd5NigQ>?		NX3CeGM1OjRiaB?=		M4\RUWlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Ehf2m2aDDJR\|UxKG:oIECuNVIh\|ryP	NUjRfotSOjN4MEK1NlM>
High5	NXHIcW1OU2mwYYPlJGF{e2G7		MWKyOEBp		M{jNR2lvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiSFTBR\|Mhf2m2aDDJR\|UxKG:oIECuNVch\|ryP	M3;KbVI{PjB{NUKz
A549	MoHWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			NXrpN25VTE2VTx?=	NF7EWlJKSzVyPUGuNFc6KM7:TR?=	MniwNlM3PDR{MUC=
HCT116	M2\6OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			MkTlSG1UVw>?	M{\GVGlEPTB;MD63OVch\|ryP	MXWyN\|Y1PDJzMB?=
K562	NIPSS25Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=			Mn\6SG1UVw>?	M1XLN2lEPTB;MD62OFUh\|ryP	NUm4ZohCOjN4NESyNVA>
GBC-SD	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXj[nY2KM7:TR?=	MoLLO\|IhcA>?	M3XmWGROW09?	MV\JR\|UxRTF2Lkig{txO	Mm\3NlM4ODd{NkC=
HGC27	MmP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkX3OUDPxE1?	MYe3NkBp	MmPzSG1UVw>?	NYLjbpU4UUN3ME21MlQh\|ryP	MV:yN\|cxPzJ4MB?=
HL60	MoK2T4lv[XOnIFHzd4F6	NGTYXYg2KM7:TR?=	NWPBTHhFOjRiaB?=	MlLmSG1UVw>?	NUHp[ZJVUW6qaXLpeIlwdiCxZjDISGFE	NXXxTHVJOjN5MEeyOlA>
Vero	NH7IUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkPrO\|IhcA>?	NUXzSJo{TE2VTx?=	MlrMTWM2OD1yLkmg{txO	MUCyN\|c5PjR3Mh?=
NCI60	NHKxZ2xEgXSxdH;4bYMhSXO\|YYm=		NFL5bos1QCCq	MV3EUXNQ	M2PsNGdKRTBwNUOg{txO	MoHjNlQxOTV\|Mke=
SW620	NYnWVXQxS3m2b4TvfIlkKEG\|c3H5		NHTXSZI1QCCq	MlG4SG1UVw>?	MorYS2k:OC53NDFOwG0>	M{nZW\|I1ODF3M{K3
U251	MWnDfZRwfG:6aXOgRZN{[Xl?		M{TXW\|Q5KGh?	MkTwSG1UVw>?	MU\HTV0yNjV\|IN88US=>	M{ntOVI1ODF3M{K3
KM12	NHPaeY9EgXSxdH;4bYMhSXO\|YYm=		MkfJOFghcA>?	NH;vVYxFVVOR	Moj3S2k:OS56ODFOwG0>	NEOweoMzPDBzNUOyOy=>
Hs578T	M3jROmN6fG:2b4jpZ{BCe3OjeR?=		M{HJZ\|Q5KGh?	Mor2SG1UVw>?	M4nUOWdKRTRwOEOg{txO	MXOyOFAyPTN{Nx?=
MDA-MB-231	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MY[0PEBp		MonGTWM2OD1yLkG2JO69VQ>?	MljpNlQxQTVyMU[=
MCF7	NUfVbnV7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX;Zb3p[PDhiaB?=		MYTHTV0xNjR3IN88US=>	NIG4emUzPDFzOUW1OS=>
MDA-MB-435	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MYO0PEBp		NHu5UFNIUT1yLki4JO69VQ>?	NWexZow{OjRzMUm1OVU>
AsPC1	NUS4PFhiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXqzNEDPxE1?	MlLrOFghcA>?	M2LVcWROW09?	NUnIfWZuUUN3ME2zMlY3KM7:TR?=	NGToVo0zPDF6NUO3PC=>
Jurkat E6.1	MWXLbY5ie2ViQYPzZZk>		NHPJc28zKGh?	MWPEUXNQ	Mm[5TY5pcWKrdHnvckBw\iCKRFHDOEB4cXSqIFnDOVAhd2ZiMD6wOEDPxE1?	MYWyOFI3OTh4Mh?=
KG1	M2PONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NInuVWU1QCCq		NXP0ZYprUUN3ME2xMlE2KM7:TR?=	MoTDNlQ2OjVyMEO=
HEL	M2fsWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoTIOFghcA>?	MVfEUXNQ	M1XtXmlEPTB;MD60PUDPxE1?	MmXoNlQ3QTRyNUW=
HSC3	M2rDbmN6fG:2b4jpZ{BCe3OjeR?=		NEHiZWcyOiCq	NXvxUpFnTE2VTx?=	MoDKTWM2OD1yLkexJO69VQ>?	M{[1cVI1PzZ4NU[w
HT-29	M1v1N2N6fG:2b4jpZ{BCe3OjeR?=		MnTlNVIhcA>?	M{ixSWROW09?	NHHjOnhKSzVyPUCuO\|Ih\|ryP	NHjYfYkzPDd4NkW2NC=>
KB	MVzDfZRwfG:6aXOgRZN{[Xl?		M3n6eVEzKGh?	NV31R2xpTE2VTx?=	NH\M[GpKSzVyPUCuO\|Uh\|ryP	M4XWU\|I1PzZ4NU[w
H460	MXjDfZRwfG:6aXOgRZN{[Xl?		Mo\zNVIhcA>?	MXrEUXNQ	NHLnZmlKSzVyPUCuPFIh\|ryP	NX3TSIJQOjR5Nk[1OlA>
MONE1	MVzDfZRwfG:6aXOgRZN{[Xl?		MoL0NVIhcA>?	NFXDdY9FVVOR	NWnINWg6UUN3ME2xMlE5KM7:TR?=	M2XjdFI1PzZ4NU[w
MKN45	MmHiR5l1d3SxeHnjJGF{e2G7		M3TDXFEzKGh?	NF;5XJNFVVOR	MmO4TWM2OD1zLkK1JO69VQ>?	MmrlNlQ4PjZ3NkC=
TSGH	NXrrc49vS3m2b4TvfIlkKEG\|c3H5		M2fNUVEzKGh?	MX;EUXNQ	NXzpRXQ2UUN3ME2yMlA6KM7:TR?=	M2X0S\|I1PzZ4NU[w
HL60	NWn4W\|I{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFn5TpI4OiCq	NX;oPY02TE2VTx?=	MVTHTVUxRTBwOUOg{txO	NVfFSZlVOjR7MEC1NFA>
HEK293	M2CzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MUe3NkBp	M{Xh[GROW09?	NEL3c3NIUTVyPUGzJO69VQ>?	NF7uSngzPDlyMEWwNC=>
Jurkat	M1PnSmN6fG:2b4jpZ{BCe3OjeR?=	MWGxNFAh\|ryP	M2[xeVczKGh?		MX7HTVUxRTBwOTFOwG0>	M{SwWFI1QTByN{Sz
GM15850	MVrLbY5ie2ViQYPzZZk>	M2iyV\|IvPSEQvF2=	NIDIXIo6PiCq	M2jlOGROW09?	M4rnboRw\XNibn;0JIlvcGmkaYSgTGRCSyCjc4Pld5Nm\CCjczDpcoNz\WG\|ZTDpckBpcXO2b37lJGg{KGy7c3nu[UAyPCCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	MXuxOlkzOTN4Nx?=
GM15850	MWPLbY5ie2ViQYPzZZk>	NFjRbZAzNjVizszN	MWe5OkBp	MXvEUXNQ	NFr3VZBld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhPSCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	NYLVUXJNOTZ7MkGzOlc>
GM15850	NXXVSJNzU2mwYYPlJGF{e2G7	M1\KZ\|IvPSEQvF2=	MkHBPVYhcA>?	MXXEUXNQ	NHrRTolld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJPCCueYPpcoUhOTJiYXPleJlt[XSrb36gc4YhTliQIHflcoU>	NX\3[\|IxOTZ7MkGzOlc>
GM15850	NVPFU3U1U2mwYYPlJGF{e2G7	NHLvfVMzNjVizszN	MW[5OkBp	NGHzbHNFVVOR	NIrDe21ld2W\|IH7veEBqdmirYnn0JGhFSUNiYYPz[ZN{\WRiYYOgbY5kemWjc3WgbY4hcGm\|dH;u[UBJOyCueYPpcoUhQSCjY3X0fYxifGmxbjDv[kBHYE5iZ3Xu[S=>	NVfVZ4ltOTZ7MkGzOlc>
GM15850	NF;6VpVMcW6jc3WgRZN{[Xl?	MYSyMlUh\|ryP	Ml\1PVYhcA>?	NHjYW4JFVVOR	Mnj2[I9meyCwb4SgbY5pcWKrdDDISGFEKGG\|c3Xzd4VlKGG\|IHnuZ5Jm[XOnIHnuJIhqe3SxbnWgTFQhdHm\|aX7lJFgh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	M4\3c\|E3QTJzM{[3
GM15850	MXTLbY5ie2ViQYPzZZk>	NYjtSIk1Oi53IN88US=>	NFHxVXo6PiCq	NV;VWXFNTE2VTx?=	MVrkc4V{KG6xdDDpcohq[mm2IFjERWMh[XO\|ZYPz[YQh[XNiaX7jdoVie2ViaX6gbIl{fG:wZTDIOEBtgXOrbnWgNVYh[WOndInsZZRqd25ib3[gSnhPKGenbnW=	NXrjc\|d4OTZ7MkGzOlc>
GM15850	NYHPOJB[TnWwY4Tpc44hSXO\|YYm=	MVq1JO69VQ>?	NVfHUI1EOTJiaB?=	NVTSRWdZTE2VTx?=	MWroZZMhdm9iZX\m[YN1KG:wIF\YUkBuWk6DIHX4dJJme3Orb36=	M2fJ[VE3QTJzM{[3
U937	M2nWNWtqdmG\|ZTDBd5NigQ>?	NWCzZlFJPSEQvF2=	M2HMS\|I1KGh?	NFP2Zo9FVVOR	MkTJbIF{KG6xIHXm[oVkfCCxbjDhcJBp[SC2dXL1cIlvKGGlZYT5cIF1cW:w	M4f1ZlE4PDR5N{Ww
U937	MXPLbY5ie2ViQYPzZZk>	MkLxNUDPxE1?	M3PPN\|I1KGh?	NUjxZox[TE2VTx?=	NYi5co1TcGG\|IH7vJIVn\mWldDDvckBidHCqYTD0eYJ2dGmwIHHj[ZR6dGG2aX;u	NYHrOGVbOTd2NEe3OVA>
PANC1	NGC3ZYxHfW6ldHnvckBCe3OjeR?=	NXnzcnBMOSEQvF2=	M4HDPVI1KGh?		NXXqZ2dZ\G:nczDuc5QhcW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	NIPMUW8yPzV6OEe0OC=>
PANC1	NF\Te5lHfW6ldHnvckBCe3OjeR?=	M4TSc\|Eh\|ryP	M1PReVQ5KCCq		NV\PUIM{\G:nczDuc5QhcW6lcnXhd4UhcW5icEK3b4lxOSCpZX7lJIV5eHKnc4Ppc44>	NECxT2YyPzV6OEe0OC=>
Caco-2	NX7aZXNxTnWwY4Tpc44hSXO\|YYm=	MWm1JO69VQ>?	MU[yOEBp	NX35UHpbTE2VTx?=	MVLkc4V{KG6xdDDpcoR2[2ViUEKxW2FHOSCpZX7lJIV5eHKnc4Ppc44>	MnHpNlAyPDN6NEC=
SCC4	Mk\oSpVv[3Srb36gRZN{[Xl?	MX6xJO69VQ>?	MXyxNEBucW5?	NIXGNWRFVVOR	MWToZZMhdm9iYXfvcol{fCCjY4Tpeol1gSCjdDDWSHIh[XO\|ZYPz[YQh[XNiaX7keYN1cW:wIH;mJGN[WDJ2IHflcoUh\XiycnXzd4lwdg>?	Ml;CNlA1PTJ{MkW=
A549	M4X5UmZ2dmO2aX;uJGF{e2G7	NHrKR\|M2KM7:TR?=	NGqwR4w{KGh?	MofMSG1UVw>?	NYHSdox2\G:nczDuc5QhcW6mdXPlJIF2fG:yaHHnfUBie3Onc4Pl[EBieyCrbnPy[YF{\SCrbjDMR\|NKUQ>?	NILyVXIzODh3NUKwPC=>
HCT116	MYrLbY5ie2ViQYPzZZk>	M{PTUVAvOyEQvF2=	M1HUPFMxKGh?	NY\2TFFFTE2VTx?=	NFHrbI9ld2W\|IH7veEBqdmirYnn0JGhFSUNzIHHzd4V{e2WmIHHzJIlv\HWldHnvckBw\iCqaYP0c45mKEh\|S{mgZYNmfHmuYYTpc44>	NWP0bnVQOjFyOEC2OFc>
HepG2	MmPOSpVv[3Srb36gRZN{[Xl?	NEThOnAyOCEQvF2=	M1PvflI1KGh?	NXKzeo9CTE2VTx?=	MkHW[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BpgXCncnHj[ZR6dGG2aX;uJI9nKHB3Mx?=	M{f0V\|IyPTR6NUiy
GM11272	MWTGeY5kfGmxbjDBd5NigQ>?	MVSwMlEh\|ryP	MkeyO\|IhcA>?	NIi2epdFVVOR	MmSw[I9meyCwb4SgdoVi[3SrdnH0[UBO\UOyMjDteZRidnRiZYjwdoV{e2mxbh?=	M4fYdFIyQDRyN{G2
MDA-MB-231	NV\pSpRVU2mwYYPlJGF{e2G7	M{fJNVExKM7:TR?=	MYO1JI1qdg>?	NXPF[m5CTE2VTx?=	M4nnfoRw\XNibn;0JIlvcGmkaYSgTGRCSzKj	M2DhV\|I{PDl\|NES5
MDA-MB-231	MlrpT4lv[XOnIFHzd4F6	NWTLTHdZOSEQvF2=	MmjWNlQhcA>?	NX21TZZOTE2VTx?=	Mlfq[I9meyCwb4SgbY5pcWKrdDDISGFEPiCjc4Pld5Nm\CCjczDhZ4V1gWyjdHnvckBt\X[nbIOgc4YhfHWkdXzpci=>	NHTNN2QzOzR7M{S0PS=>
K562	NHTpcGFMcW6jc3WgRZN{[Xl?				MWXkc4V{KG6xdDDpcohq[mm2IFjERWM>	MYOyN\|U6OTFzMR?=
Jurkat	MkjHR5l1d3SxeHnjJGF{e2G7	MkLRNlAh\|ryP	NUDoWVFsPzJiaB?=	NFjHNYpFVVOR	MkfPco8h[3m2b4TvfIlkcXS7IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;u	NYTnSHBxOjR\|MESzOFg>
HCT116	M{HzZ2Fxd3C2b4Ppd{BCe3OjeR?=	MnzuN{DPxE1?	Mk\uNlQhcA>?	M33vR2ROW09?	Moi0[I9meyCwb4SgbY5lfWOnIHHwc5B1d3OrczDhd5Nme3OnZDDhd{BqdmO{ZXHz[UBqdiCyNUOgdJJwfGWrbjDs[ZZmdA>?	NFPDPGEzPDd4NkW2NC=>
KASUMI-1	NGPXUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TV[GlEPTB;OUmuNVchdk1?	M1XDOXNCVkeHUh?=
KARPAS-45	M{njNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPGUJFKSzVyPUG3N{45QSCwTR?=	NH7ieFVUSU6JRWK=
BHT-101	NFnPW5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXkTWM2OD1{NESuNVghdk1?	MYXTRW5ITVJ?
H9	M1LIV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfpOnVKSzVyPUK1OU4xPCCwTR?=	NV[1TXNJW0GQR1XS
PA-1	M2X5[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3n5dmlEPTB;Mki2MlI3KG6P	MoTwV2FPT0WU
NEC8	Ml;YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHPOXZNKSzVyPUK4PU4{QCCwTR?=	NIjad5pUSU6JRWK=
MHH-PREB-1	NGPSXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HLUGlEPTB;Mkm0MlU{KG6P	NY\nPIZHW0GQR1XS
NB7	MmXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHMcZZxUUN3ME2zOFUvPzRibl2=	Mn\ZV2FPT0WU
A3-KAW	MnTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\DbmRKUUN3ME20NFAvPTlibl2=	NWLQVIUyW0GQR1XS
NB69	M4HSeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HvVWlEPTB;NEGxMlcyKG6P	Mkn2V2FPT0WU
EoL-1-cell	NH;jepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV;JR\|UxRTR3NEK1JI5O	NU[1ZVlyW0GQR1XS
CHP-212	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTR3Nz61N{BvVQ>?	MlPiV2FPT0WU
C2BBe1	NEP1cGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEXZbIhKSzVyPUS3Nk4yQSCwTR?=	M3PnfXNCVkeHUh?=
697	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkCzTWM2OD12N{OuOFEhdk1?	NWjScFUzW0GQR1XS
BCPAP	MlK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTVyMT60NkBvVQ>?	M2izUHNCVkeHUh?=
L-363	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnhPVdwUUN3ME21NFMvOSCwTR?=	MUnTRW5ITVJ?
ES8	NH3CdFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHi5b3NKSzVyPUWyN{42OyCwTR?=	NY\SPJBQW0GQR1XS
BE-13	M{HVSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYnibXhXUUN3ME21NlYvQTZibl2=	NWrzUHBwW0GQR1XS
CTB-1	M3XzdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmraTWM2OD13M{euPVIhdk1?	M{e4bXNCVkeHUh?=
HD-MY-Z	MoqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NW\yW3pDUUN3ME21N\|gvOTNibl2=	NVHzb\|BsW0GQR1XS
NKM-1	MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTV2ND6yO{BvVQ>?	MlO0V2FPT0WU
NCI-H720	M1roR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3ywWGlEPTB;NU[wMlE5KG6P	MXnTRW5ITVJ?
KY821	M3rJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHThXpBKSzVyPUW2N{4zPSCwTR?=	MnHmV2FPT0WU
OVCAR-5	M4HTNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlP6TWM2OD13N{[uNVEhdk1?	Ml70V2FPT0WU
CTV-1	MlrkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NILVOmRKSzVyPUW4NU42PiCwTR?=	MonUV2FPT0WU
P12-ICHIKAWA	MknrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDpXHZKSzVyPUW5Ok42OSCwTR?=	NH7EUVNUSU6JRWK=
DB	NETxcpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUjJR\|UxRTV7OD61O{BvVQ>?	NFX3fIdUSU6JRWK=
CHL-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnnQTWM2OD14NEKuNFghdk1?	MYjTRW5ITVJ?
A4-Fuk	MnfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkW4TWM2OD14NESuPVEhdk1?	NVvUZmtvW0GQR1XS
MV-4-11	M1;URWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfLTWM2OD14NUmuNUBvVQ>?	MUDTRW5ITVJ?
RPMI-8226	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrwfG1UUUN3ME22O\|gvOThibl2=	M1\QUnNCVkeHUh?=
NB14	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3jSbGlEPTB;Nkm2Mlk2KG6P	NEW1eJhUSU6JRWK=
DOHH-2	Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TtbWlEPTB;N{C2MlY5KG6P	M3qyUHNCVkeHUh?=
D-423MG	Ml;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXj1VJdbUUN3ME23NFYvQDlibl2=	NUS5dnRjW0GQR1XS
D-283MED	NUDib2Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHG5Z5hKSzVyPUexOE4yPCCwTR?=	NH:0VXhUSU6JRWK=
ES1	M4Hn[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFu0VVFKSzVyPUeyOE41KG6P	M1XGbXNCVkeHUh?=
GOTO	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTd{OT6xNkBvVQ>?	MlzoV2FPT0WU
NCI-H209	NGPDb\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTd{OT65JI5O	MnTBV2FPT0WU
MOLT-13	NFnIbHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHnTfI5KSzVyPUezPE46QCCwTR?=	Mk\nV2FPT0WU
ATN-1	M1[yNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH;BUphKSzVyPUe0NE4zQCCwTR?=	NEi1TZBUSU6JRWK=
DU-4475	M{TJfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTd3MT65NUBvVQ>?	NWXjeId3W0GQR1XS
NB10	M33aRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYDwdlFMUUN3ME23OVEvQTJibl2=	NXXTbGNPW0GQR1XS
KG-1	MoTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLIOndKSzVyPUe3OU41PSCwTR?=	M2nYS3NCVkeHUh?=
MOLT-4	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHZTWM2OD15OEeuOFYhdk1?	NFmzZWpUSU6JRWK=
TE-1	NF;hZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmX2TWM2OD15OUGuNUBvVQ>?	M4\WOnNCVkeHUh?=
SBC-1	M3fMS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVOyN2NLUUN3ME23PVMvQDRibl2=	M2[xcnNCVkeHUh?=
HEL	NIOxXIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NULWS4tvUUN3ME24NFYvODhibl2=	MonoV2FPT0WU
SK-MEL-2	NEG0flJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3rOUGlEPTB;OEC5MlQ1KG6P	MWPTRW5ITVJ?
KU812	MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjkSm5CUUN3ME24NVMvOSCwTR?=	NXG3SlJvW0GQR1XS
RPMI-8866	NWTYepZRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF;kd3lKSzVyPUixN{43PyCwTR?=	NHXlXpZUSU6JRWK=
ALL-PO	NX7LZ\|RrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILl[nZKSzVyPUixOE43PiCwTR?=	MUXTRW5ITVJ?
LU-139	M{Wxe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\TdGlEPTB;OEKyMlg3KG6P	NHvRVJZUSU6JRWK=
RS4-11	NUHUb3UyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYnJR\|UxRTh\|Mj60OUBvVQ>?	NIDLV3FUSU6JRWK=
EW-18	M3PTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTh\|Mj65OkBvVQ>?	Ml\EV2FPT0WU
P30-OHK	MlzmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NISyeI9KSzVyPUizOU44KG6P	M2KyOnNCVkeHUh?=
D-566MG	NHvvVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfFd2pKSzVyPUizPE43OiCwTR?=	NX3URpN6W0GQR1XS
HSC-4	MoPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoixTWM2OD16NE[uOVEhdk1?	Mlv6V2FPT0WU
QIMR-WIL	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4nGXWlEPTB;OE[yMlA{KG6P	NFX1SmJUSU6JRWK=
SW954	M2XVfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTh4Mz6xOkBvVQ>?	NVLRT5h4W0GQR1XS
HGC-27	M3TXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTh5Mj6zOEBvVQ>?	NH;Xd2xUSU6JRWK=
HH	NFH6bmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1\XcWlEPTB;OEm0MlEzKG6P	NUXyW49nW0GQR1XS
KE-37	M3LhOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PrS2lEPTB;OEm0MlYzKG6P	NUHINFBkW0GQR1XS
SK-N-DZ	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk[1TWM2OD17MECuOFMhdk1?	M1LxcXNCVkeHUh?=
J-RT3-T3-5	NF;xcFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTCTWM2OD17MUCuOFkhdk1?	NVjpZlJRW0GQR1XS
A427	NFPKN4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmj0TWM2OD17MkCuPFQhdk1?	NHXaWm5USU6JRWK=
ECC10	NYLFd5JYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTUTWM2OD17NEWuPFchdk1?	Ml\YV2FPT0WU
EW-1	M1r4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkCzTWM2OD17NEeuNlYhdk1?	MVrTRW5ITVJ?
MIA-PaCa-2	MlLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHRTWM2OD17NEmuNVIhdk1?	NXzJfpFWW0GQR1XS
HCC2218	NH6zfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUXJR\|UxRTl3OD60PEBvVQ>?	MXfTRW5ITVJ?
HAL-01	NX\0XIF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYP0R\|BIUUN3ME25OlgvODRibl2=	Ml7qV2FPT0WU
RD	M{HWfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTl5ND60OUBvVQ>?	M1TGfnNCVkeHUh?=
SK-N-AS	NYC4RmZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M360SGlEPTB;OUi4MlEhdk1?	NWLtdmxSW0GQR1XS
ML-2	MkLRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmniTWM2OD1zLkCwOFA4KM7:TR?=	NIjJ[JpUSU6JRWK=
MEL-HO	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnW3TWM2OD1zLkCwOVgzKM7:TR?=	NGTrV5hUSU6JRWK=
MS-1	NYfseGRLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjRXFFKSzVyPUGuNFA3OTdizszN	MYnTRW5ITVJ?
NCI-SNU-1	M4\3T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGXQPJNKSzVyPUGuNFI{OzFizszN	MkjmV2FPT0WU
8505C	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvUWnp2UUN3ME2xMlAzOzNzIN88US=>	Mo\1V2FPT0WU
MN-60	Mn7MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXPGe2hVUUN3ME2xMlAzPjhizszN	MlvJV2FPT0WU
SAS	NFPKRYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nWW2lEPTB;MT6wOFA5OSEQvF2=	MoLSV2FPT0WU
EFM-19	NUTNUlN5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4SxNWlEPTB;MT6wOFg4QSEQvF2=	MWPTRW5ITVJ?
Ca9-22	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;TTWM2OD1zLkC1NVA4KM7:TR?=	NWnpN4VNW0GQR1XS
NBsusSR	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrDTWM2OD1zLkC1NVY3KM7:TR?=	NIjReG5USU6JRWK=
NB13	MlzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NESwWpBKSzVyPUGuNFU2ODFizszN	M{TCUnNCVkeHUh?=
SF295	NEiy[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7TNINpUUN3ME2xMlA3PjJ2IN88US=>	MX;TRW5ITVJ?
U-2-OS	MkL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHONGVKSzVyPUGuNFc6OTFizszN	M3G5NHNCVkeHUh?=
NCI-H526	NV7vUmZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33nOGlEPTB;MT6wPFI6OSEQvF2=	Ml7tV2FPT0WU
KMOE-2	NYG5UZpIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLFTWM2OD1zLkC5OFIzKM7:TR?=	NHyzTplUSU6JRWK=
RCM-1	M2D5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1OzN2lEPTB;MT6xNlExOiEQvF2=	MmPFV2FPT0WU
MC116	NYj1PGY{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITkTmdKSzVyPUGuNVM3OjFizszN	MX3TRW5ITVJ?
NCI-H1092	M{L3TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXrJR\|UxRTFwMUW0NFYh\|ryP	NVzRcWJpW0GQR1XS
EW-3	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEi4cFVKSzVyPUGuNVczOTJizszN	Moi5V2FPT0WU
HCT-116	M2DSVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmX1TWM2OD1zLkG3O\|Uh\|ryP	NG\yVJhUSU6JRWK=
MC-IXC	NEP0Zm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLXTWM2OD1zLkG3PFgyKM7:TR?=	NHTqWWhUSU6JRWK=
LB1047-RCC	MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGjTN2dKSzVyPUGuNVg{OTJizszN	NFvXVm5USU6JRWK=
VM-CUB-1	M2PUdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHf4TY1KSzVyPUGuNVkyODhizszN	MlKyV2FPT0WU
NB5	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGHHcI5KSzVyPUGuNVk5PTZizszN	NWHK[Yd6W0GQR1XS
SKG-IIIa	NGTGV4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTFwMkO0OlQh\|ryP	M{eySXNCVkeHUh?=
HO-1-N-1	NWDqfmJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4jE[WlEPTB;MT6yN\|g{PSEQvF2=	MoLQV2FPT0WU
EFO-27	M4K1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYS1cIJWUUN3ME2xMlI2ODR\|IN88US=>	Ml\VV2FPT0WU
MHH-NB-11	M4LaZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkL5TWM2OD1zLkK4N\|I6KM7:TR?=	NWq1c5F{W0GQR1XS
SW620	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rmOmlEPTB;MT6yPVAyQCEQvF2=	M{PM[nNCVkeHUh?=
MOLT-16	M2\HO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NILlUYxKSzVyPUGuNlk4QTdizszN	MXvTRW5ITVJ?
NTERA-S-cl-D1	MoX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzMWllxUUN3ME2xMlMyPzZzIN88US=>	MXfTRW5ITVJ?
VA-ES-BJ	NUfueHprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHuxS\|RKSzVyPUGuN\|I1PzdizszN	MnXhV2FPT0WU
HCC1419	M4m1fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV7MeVBqUUN3ME2xMlM1ODJ5IN88US=>	MX\TRW5ITVJ?
NCI-H69	M1HlVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIHPcIVKSzVyPUGuN\|QyOTJizszN	NUXtdo9zW0GQR1XS
DEL	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmrhTWM2OD1zLkO1NVYzKM7:TR?=	MVzTRW5ITVJ?
LXF-289	NH3DXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlzETWM2OD1zLkO1NlQh\|ryP	MWfTRW5ITVJ?
EW-11	MknES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoP6TWM2OD1zLkO2NFI3KM7:TR?=	MofZV2FPT0WU
KP-4	MmD6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHK[VljUUN3ME2xMlM4ODh3IN88US=>	NH;KdXZUSU6JRWK=
NOS-1	MkHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnaSmZKSzVyPUGuOFEyQTRizszN	NIDne3JUSU6JRWK=
SK-NEP-1	NYnyTm5MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXGTWM2OD1zLkSxOlk{KM7:TR?=	MYDTRW5ITVJ?
LAMA-84	M1rX[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEHZcXNKSzVyPUGuOFM6PDVizszN	MX7TRW5ITVJ?
ES5	M2jIPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXwR3hsUUN3ME2xMlQ1OyEQvF2=	MnXVV2FPT0WU
HuO9	NEDDb5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTvTWM2OD1zLkS1N\|YzKM7:TR?=	M1jsc3NCVkeHUh?=
COLO-684	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTmTplKSzVyPUGuOFYyOThizszN	NIC0RmlUSU6JRWK=
EW-24	M{\Yb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml[yTWM2OD1zLkS2OVMyKM7:TR?=	M4fyVHNCVkeHUh?=
BV-173	M1zoeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX7IZlZwUUN3ME2xMlQ4OjlzIN88US=>	NUn2e2VqW0GQR1XS
NCI-H1770	Mlr5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTFwNEi1N\|Yh\|ryP	M1fZNHNCVkeHUh?=
HuP-T4	M37T[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWP2XVVkUUN3ME2xMlQ6OyEQvF2=	NIPiSIRUSU6JRWK=
TYK-nu	MoT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofITWM2OD1zLkS5PFUyKM7:TR?=	M{PrRXNCVkeHUh?=
YH-13	NVj1S4VoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3hTWM2OD1zLkS5PFk1KM7:TR?=	NHvxdIVUSU6JRWK=
H4	Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfaRY9CUUN3ME2xMlUxQTF{IN88US=>	M2\oVnNCVkeHUh?=
OVCAR-8	NWD2fldWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkn2TWM2OD1zLkW0OFc4KM7:TR?=	MUXTRW5ITVJ?
NCI-H23	M1XySmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTFwNUS2OFUh\|ryP	MkjJV2FPT0WU
ES7	NVvpWpVOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XaOGlEPTB;MT61OFc4OyEQvF2=	MV3TRW5ITVJ?
COR-L88	NYT4S2JpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjNTWM2OD1zLkW2OFI1KM7:TR?=	NXrKUm1jW0GQR1XS
TI-73	M{DOUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWX2eWJSUUN3ME2xMlU6ODZizszN	NVHzXXJnW0GQR1XS
RT-112	MkftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1T0RmlEPTB;MT61PVI5PCEQvF2=	NYjaWplXW0GQR1XS
HuO-3N1	M36yRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTFwNUmzPFUh\|ryP	MnLmV2FPT0WU
HC-1	NXW4XZBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjaemFKSzVyPUGuOVk5PjZizszN	M{fpR3NCVkeHUh?=
HT55	NFrZS4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rTSmlEPTB;MT62OVE{OSEQvF2=	MYTTRW5ITVJ?
IA-LM	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjMb2NKSzVyPUGuOlkzPzhizszN	M4foeHNCVkeHUh?=
EM-2	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXzJR\|UxRTFwN{CwNVQh\|ryP	MoXCV2FPT0WU
MHH-ES-1	NGfqWZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYmzXWQ6UUN3ME2xMlcxPDN3IN88US=>	M1SxUHNCVkeHUh?=
CAL-27	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHFTWM2OD1zLkewOlIyKM7:TR?=	NUS2SmV2W0GQR1XS
COLO-800	NYjWdm9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHO3RnVKSzVyPUGuO\|EyPzlizszN	NUfSVYdtW0GQR1XS
HCE-T	M3\wfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLOTWM2OD1zLkexOUDPxE1?	M2HqTnNCVkeHUh?=
CAMA-1	MmLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTFwN{G5O\|Eh\|ryP	NXTWdmc2W0GQR1XS
LOXIMVI	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mly3TWM2OD1zLkeyNVEh\|ryP	NH;0Z2ZUSU6JRWK=
NH-12	M3K5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmG0TWM2OD1zLkeyOlkyKM7:TR?=	NYfrcIM4W0GQR1XS
TCCSUP	MoeyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYrRfJhuUUN3ME2xMlczQDJ7IN88US=>	M{KzNHNCVkeHUh?=
MDA-MB-361	NUDnNm9HT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDMOnZKSzVyPUGuO\|MyPTdizszN	NFfBdZhUSU6JRWK=
EW-16	MoS3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4PtPWlEPTB;MT63OFExPyEQvF2=	MX7TRW5ITVJ?
SNU-423	M3fNO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYDJR\|UxRTFwN{W4Nlch\|ryP	Mn\oV2FPT0WU
Daoy	M3LocGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzBdVZKSzVyPUGuO\|Y{OTlizszN	MoHOV2FPT0WU
ES4	M3jZbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTFwN{i3OFEh\|ryP	MWPTRW5ITVJ?
PFSK-1	MkLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPjTWM2OD1zLkiwN\|ch\|ryP	M3nhUnNCVkeHUh?=
ES3	NWXs[ZFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWrmbIJEUUN3ME2xMlgzPjhzIN88US=>	MoOyV2FPT0WU
ONS-76	M1nTbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml6yTWM2OD1zLkiyPFk4KM7:TR?=	MXXTRW5ITVJ?
JVM-3	NXTsVnEzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTFwOEW0OVEh\|ryP	NVLXRmNMW0GQR1XS
OS-RC-2	M{HOVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzqcI9XUUN3ME2xMlg4OTVzIN88US=>	NGjQUY9USU6JRWK=
COLO-320-HSR	NXvpeI1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vxTGlEPTB;MT64PFE6PyEQvF2=	NWfOPJgyW0GQR1XS
HN	Mm\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrLTWM2OD1zLki4O\|I2KM7:TR?=	NVvqem86W0GQR1XS
HT	MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYjMcIJCUUN3ME2xMlg5QTR5IN88US=>	MoLaV2FPT0WU
LoVo	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVrwbYJWUUN3ME2xMlg6QDFizszN	NYHDTItzW0GQR1XS
CGTH-W-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXfwdG5PUUN3ME2xMlg6QTR4IN88US=>	MojLV2FPT0WU
NB6	MlzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXrLXGFvUUN3ME2xMlkyOjl6IN88US=>	M4XiVnNCVkeHUh?=
EW-22	NUOw[nBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV7JR\|UxRTFwOUK4PFch\|ryP	Ml:4V2FPT0WU
ES6	MkPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTFwOUO2N\|Eh\|ryP	MkTpV2FPT0WU
SCC-15	M4LGV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlTNTWM2OD1zLkmzPFE6KM7:TR?=	NFi3V4xUSU6JRWK=
HL-60	NHjNRYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHudIZKSzVyPUGuPVM6ODJizszN	NGP6NWJUSU6JRWK=
human HOP-92	MmS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\ueGlEPTB;MT65OFA3PSEQvF2=	M1nFd3NCVkeHUh?=
SW626	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGO5UVBKSzVyPUGuPVQ5QTlizszN	MUDTRW5ITVJ?
HEC-1	NWPtZY12T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFPmU4xKSzVyPUGuPVU{PiEQvF2=	NFvpeoRUSU6JRWK=
LB2241-RCC	NXyxbYpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTFwOUiyN\|Eh\|ryP	NXrQZ3JFW0GQR1XS
Ramos-2G6-4C10	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NI\tPYtKSzVyPUGuPVk1QTNizszN	M4n6c3NCVkeHUh?=
A101D	Mof4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoP2TWM2OD1{LkKwN\|A{KM7:TR?=	Mnr3V2FPT0WU
NCI-H446	M1LJTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfRfHdKSzVyPUKuNFQ2QTlizszN	M3rPXXNCVkeHUh?=
SBC-5	MorQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWLJR\|UxRTJwME[xOFch\|ryP	NXW2bmhCW0GQR1XS
HOS	NFrpPZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3[3fGlEPTB;Mj6wO\|Y2OyEQvF2=	NYHsR\|dxW0GQR1XS
K5	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjDfINKSzVyPUKuNFc5OTFizszN	NY\sWHlHW0GQR1XS
HLE	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnUTWM2OD1{LkC4OVI6KM7:TR?=	MofnV2FPT0WU
HSC-2	NHH2bmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2ewc2lEPTB;Mj6xNlg6QCEQvF2=	MWfTRW5ITVJ?
LCLC-97TM1	NUDoeVR2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkPoTWM2OD1{LkG0OVg{KM7:TR?=	NYrBPYk3W0GQR1XS
DMS-273	MmHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4C0XGlEPTB;Mj6xOFg{PyEQvF2=	NX3tO5FyW0GQR1XS
TE-8	NGnZeZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3H2O2lEPTB;Mj6xOVc3PSEQvF2=	M4\BWnNCVkeHUh?=
DSH1	MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXtTWM2OD1{LkG2N\|k5KM7:TR?=	NE\1TFZUSU6JRWK=
CAL-51	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX7JR\|UxRTJwMU[2PVkh\|ryP	NETSO3VUSU6JRWK=
IST-SL1	MoWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfTWm9JUUN3ME2yMlE3QDR2IN88US=>	MnzCV2FPT0WU
GCT	NXPkVoxbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NW\HbmdSUUN3ME2yMlE4PzdizszN	NVztZmpSW0GQR1XS
SW948	NHnWR2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUXFRo9vUUN3ME2yMlE5PDV4IN88US=>	M17yU3NCVkeHUh?=
NOMO-1	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWP3d\|BOUUN3ME2yMlE6OzF5IN88US=>	M2rOZ3NCVkeHUh?=
C8166	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTJwMkGzN\|Qh\|ryP	M3LwXXNCVkeHUh?=
OC-314	M3fteGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPxXohKSzVyPUKuNlMzPTlizszN	M1PER3NCVkeHUh?=
CAL-39	NFTubZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHn1WoNKSzVyPUKuNlM3OjZizszN	MWLTRW5ITVJ?
MDA-MB-453	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVjJR\|UxRTJwMkSyO\|Uh\|ryP	NGD5OWNUSU6JRWK=
A673	NF\YdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnTiTWM2OD1{LkK1PFYzKM7:TR?=	Mn3SV2FPT0WU
HTC-C3	NHHhe3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13r[mlEPTB;Mj6yOlg2KM7:TR?=	NWLHNoNGW0GQR1XS
NCI-H1666	NUXFcYFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX\pZm9iUUN3ME2yMlI5OTFzIN88US=>	MmnmV2FPT0WU
PSN1	MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MofMTWM2OD1{LkK4PVE{KM7:TR?=	NHToTlNUSU6JRWK=
GI-1	M17TWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTZRolYUUN3ME2yMlMxPTR\|IN88US=>	MoCyV2FPT0WU
HuH-7	M1roNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVX1cnNMUUN3ME2yMlMxPjN5IN88US=>	MmrWV2FPT0WU
JAR	M{O3Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml3wTWM2OD1{LkOxPVg4KM7:TR?=	NGnxdFVUSU6JRWK=
5637	NHPNc5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4Lx[WlEPTB;Mj6zNlEzQSEQvF2=	M2DReXNCVkeHUh?=
GB-1	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEjXNXBKSzVyPUKuN\|I{OzVizszN	MWTTRW5ITVJ?
KP-N-YS	NFL5[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M17EZWlEPTB;Mj6zNlYyPSEQvF2=	MYLTRW5ITVJ?
OAW-42	NF7LU\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7BTWM2OD1{LkOzOFE3KM7:TR?=	MYTTRW5ITVJ?
8-MG-BA	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTJwM{O5NFYh\|ryP	MlTYV2FPT0WU
RH-18	MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHERXlOUUN3ME2yMlM2ODJ{IN88US=>	NY\VR3lNW0GQR1XS
NCI-H1155	NEfrbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rEc2lEPTB;Mj6zOlczPSEQvF2=	NEj0boJUSU6JRWK=
NB17	NWnPOlFUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTJwM{iyOFMh\|ryP	MUTTRW5ITVJ?
NCI-H1437	NFrhZotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3Lh[WlEPTB;Mj60NVg4OyEQvF2=	NXPiRm5KW0GQR1XS
SN12C	NX21[WxQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTJwNEOyNVQh\|ryP	MVfTRW5ITVJ?
HSC-3	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUnwSJZXUUN3ME2yMlQ1PTB7IN88US=>	MWHTRW5ITVJ?
GAMG	NEDuSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPZPHFKSzVyPUKuOFQ2PjFizszN	NVTmSWVzW0GQR1XS
HT-1080	NXvPfpJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrnTXcxUUN3ME2yMlQ1QDZ2IN88US=>	MV3TRW5ITVJ?
A549	MofiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fDTmlEPTB;Mj60OFg6OyEQvF2=	Mn3vV2FPT0WU
KNS-62	NE\hS3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWO0WoF4UUN3ME2yMlQ2ODZzIN88US=>	NGXwfHpUSU6JRWK=
YKG-1	M{LUOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWntfGZHUUN3ME2yMlQ2PDN5IN88US=>	M3i3bnNCVkeHUh?=
LU-134-A	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTJwNEewNFgh\|ryP	MkCyV2FPT0WU
FADU	NYfjRY5CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjW[WN4UUN3ME2yMlQ4OTZ{IN88US=>	MY\TRW5ITVJ?
TGBC11TKB	NHfvTJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LSW2lEPTB;Mj60O\|E4PyEQvF2=	MlrDV2FPT0WU
HT-3	M1TZV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEPrS2VKSzVyPUKuOFk2OzVizszN	NVfWNIRkW0GQR1XS
NCI-H2170	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXTiS2ZsUUN3ME2yMlUxPTR7IN88US=>	NGLufGFUSU6JRWK=
Mo-T	M{TsW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV31d2JZUUN3ME2yMlUxQTJ5IN88US=>	MoLPV2FPT0WU
CCRF-CEM	NXXj[3M5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUn6SFJXUUN3ME2yMlU{ODR\|IN88US=>	NGTUUoVUSU6JRWK=
KU-19-19	M3HIeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXXJR\|UxRTJwNUO1NVMh\|ryP	NHjSWYJUSU6JRWK=
NCI-H1048	NF;ueIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{L0T2lEPTB;Mj61OVAzPSEQvF2=	NWriSYZjW0GQR1XS
KOSC-2	MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7YS441UUN3ME2yMlU3ODd4IN88US=>	MYHTRW5ITVJ?
A431	Mo\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTJwNU[zN\|Uh\|ryP	NX23XIVDW0GQR1XS
COR-L23	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnXOTWM2OD1{LkW4OVY3KM7:TR?=	M2fYeXNCVkeHUh?=
MKN28	NH3nTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3ZNZpKSzVyPUKuOVkxOzdizszN	MnXSV2FPT0WU
22RV1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXPJR\|UxRTJwNUmyO\|Qh\|ryP	MnPBV2FPT0WU
ABC-1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTJwNkC0OkDPxE1?	MWLTRW5ITVJ?
NCI-H2126	M3jVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVfOeot{UUN3ME2yMlYxQTh2IN88US=>	M1H5OnNCVkeHUh?=
DoTc2-4510	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVroVmlCUUN3ME2yMlYzOTh3IN88US=>	M33BWHNCVkeHUh?=
SCC-4	M2\nVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4DReGlEPTB;Mj62N\|AyOiEQvF2=	NHXJe\|VUSU6JRWK=
NCI-H661	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlnMTWM2OD1{Lk[0NFg2KM7:TR?=	MYfTRW5ITVJ?
RPMI-2650	M1z0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfJc\|lKSzVyPUKuOlQyPDNizszN	M{fWTHNCVkeHUh?=
NCI-H510A	Ml[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjPTWM2OD1{Lk[0OFI3KM7:TR?=	NUHlT3c2W0GQR1XS
BPH-1	MmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Oy[mlEPTB;Mj62OVg2KM7:TR?=	MYfTRW5ITVJ?
M14	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmTaTWM2OD1{Lk[2PVk{KM7:TR?=	M{nsUXNCVkeHUh?=
G-402	NW\JNlBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M164[2lEPTB;Mj63NFQ2OSEQvF2=	MnfJV2FPT0WU
AsPC-1	MnHxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPqZWhKSzVyPUKuO\|EyPyEQvF2=	M3G4[XNCVkeHUh?=
NB12	M3:0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUixOpBzUUN3ME2yMlcyPzFizszN	NUDQN2FTW0GQR1XS
SK-HEP-1	NFzhb4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{X0eGlEPTB;Mj63OFM6OSEQvF2=	M4fMTnNCVkeHUh?=
U-266	NXvWcIVqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NELh[3dKSzVyPUKuO\|cyOjFizszN	M1HGUnNCVkeHUh?=
AM-38	NVz0Z2s6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\ZTmlEPTB;Mj63O\|M2PSEQvF2=	NFLXd4RUSU6JRWK=
PC-14	NHXnNZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2O0XmlEPTB;Mj64NFUyKM7:TR?=	MVrTRW5ITVJ?
EGI-1	NXnHb5FDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MY\JR\|UxRTJwOEG3OFMh\|ryP	Mkn4V2FPT0WU
LS-411N	M4fPTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3rofWlEPTB;Mj64NlM{KM7:TR?=	NXP5bYhOW0GQR1XS
BFTC-905	M1riXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF[z[o1KSzVyPUKuPFU2OjNizszN	NETYdmJUSU6JRWK=
CaR-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH6ydnBKSzVyPUKuPFYh\|ryP	NULOTmxvW0GQR1XS
NCI-H292	NGfxWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4DV[2lEPTB;Mj64OlU6PiEQvF2=	MYTTRW5ITVJ?
8305C	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jBcmlEPTB;Mj64OlY1PSEQvF2=	NUnmfllzW0GQR1XS
SNU-449	NELNWJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NE[ySpJKSzVyPUKuPFkyQDJizszN	NY\vcY1VW0GQR1XS
LCLC-103H	NETYOWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF3HPZRKSzVyPUKuPVA1OzhizszN	MXXTRW5ITVJ?
SW1573	NGHnendIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHj6V4RKSzVyPUKuPVYxQDJizszN	M3\rSnNCVkeHUh?=
MLMA	Mn[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDyOZNKSzVyPUKuPVY4OTdizszN	NF\yZldUSU6JRWK=
NCI-H1355	M1z6bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XRW2lEPTB;Mz6wNFc6PiEQvF2=	MknqV2FPT0WU
RMG-I	NFvBemFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInocZZKSzVyPUOuNFI2QTJizszN	MVHTRW5ITVJ?
BB65-RCC	M2XV[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHOeHhWUUN3ME2zMlA{OzF2IN88US=>	M{f6dXNCVkeHUh?=
PC-3	MlHrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;EXZVTUUN3ME2zMlA{QDd2IN88US=>	NWCzOVg2W0GQR1XS
SF268	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHvab2JKSzVyPUOuNFQ2OjNizszN	NYf2UXBjW0GQR1XS
NCI-H810	MkTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTNwMES4NlMh\|ryP	M3fTdXNCVkeHUh?=
MEG-01	NEHmOlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWfJd\|llUUN3ME2zMlA3OTZ2IN88US=>	NGfzNG5USU6JRWK=
SW13	MnK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vFOmlEPTB;Mz6wO\|g1PyEQvF2=	MWLTRW5ITVJ?
RH-1	M3T4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1XBSGlEPTB;Mz6xNFI4QCEQvF2=	MU\TRW5ITVJ?
GT3TKB	NWDtZohjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXyTWM2OD1\|LkGxNlg{KM7:TR?=	MkLzV2FPT0WU
TK10	M1;OdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1;NUGlEPTB;Mz6xN\|czPCEQvF2=	M{LmcHNCVkeHUh?=
T-24	MnX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTNwMUWwO{DPxE1?	NHHxSmtUSU6JRWK=
A498	NGDJZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4HjWmlEPTB;Mz6yNFg4OSEQvF2=	MWHTRW5ITVJ?
GR-ST	NX\hZYFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH;qSnJKSzVyPUOuNlIyOzlizszN	MXfTRW5ITVJ?
LB2518-MEL	MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVjM[2FwUUN3ME2zMlIzOzl6IN88US=>	MWLTRW5ITVJ?
T47D	NVTjUFFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPlTWM2OD1\|LkKzOlI4KM7:TR?=	MVPTRW5ITVJ?
NCI-H1651	MlfpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzmN41KSzVyPUOuNlQ3PDRizszN	NHvUOWFUSU6JRWK=
EC-GI-10	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjYNFhoUUN3ME2zMlI3OTV\|IN88US=>	NUfTZY1NW0GQR1XS
HT-29	NF3ybZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTNwMk[2NVQh\|ryP	MUXTRW5ITVJ?
GI-ME-N	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4n5WmlEPTB;Mz6yPVUyOSEQvF2=	NF3CS5dUSU6JRWK=
SW756	M{PkSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWLJR\|UxRTNwMkm2Nlkh\|ryP	MnT6V2FPT0WU
RKO	MnrlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPJR\|UxRTNwM{C3OVch\|ryP	MljKV2FPT0WU
NCI-H1563	MnjwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\rVVJKSzVyPUOuN\|MxOThizszN	NEPPZ4JUSU6JRWK=
DJM-1	M4XoNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXHJR\|UxRTNwM{e2O\|Qh\|ryP	MkjnV2FPT0WU
L-428	NV:2XHQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlvxTWM2OD1\|LkSwNFQ2KM7:TR?=	MX3TRW5ITVJ?
NCI-H2122	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\X[IFKSzVyPUOuOFE{OTJizszN	NYnCNoxkW0GQR1XS
Ca-Ski	NXPiVIhGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml;xTWM2OD1\|LkS1OFMh\|ryP	MVzTRW5ITVJ?
639-V	NH7RUYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTNwNE[wOVch\|ryP	NF;EbHRUSU6JRWK=
SW1116	NVXi[492T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH7mWJdKSzVyPUOuOFYzPjlizszN	MWfTRW5ITVJ?
DMS-114	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXLJR\|UxRTNwNEewOlYh\|ryP	Mmr4V2FPT0WU
MZ2-MEL	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEC5bIVKSzVyPUOuOFc3QDFizszN	NXHL[FhzW0GQR1XS
COLO-829	M2WyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTNwNUCwO\|Mh\|ryP	NIL4WJlUSU6JRWK=
J82	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1TzUmlEPTB;Mz61NFU4KM7:TR?=	MoDQV2FPT0WU
EW-13	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV3JR\|UxRTNwNUK1NUDPxE1?	Mnn5V2FPT0WU
RXF393	NVLNNY9DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTNwNUOyPVQh\|ryP	NIezdHVUSU6JRWK=
CAL-62	M2HKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEiwVHVKSzVyPUOuOVQ2OTRizszN	MXPTRW5ITVJ?
OCUB-M	MmjCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTNwNUS2OlUh\|ryP	NU[yfGd[W0GQR1XS
BT-474	MnjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVnJR\|UxRTNwNkOzNUDPxE1?	M4fI[3NCVkeHUh?=
KYSE-180	MmXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfpeVJKSzVyPUOuOlM{PzJizszN	MYDTRW5ITVJ?
NCI-H650	NVnxSYp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFm5W\|FKSzVyPUOuOlQzQDdizszN	M3XCWHNCVkeHUh?=
Detroit562	NFX6eJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXETWM2OD1\|Lk[1NFIzKM7:TR?=	MYnTRW5ITVJ?
SW48	M3\Ofmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTNwNkW2OVch\|ryP	NXHqOZdYW0GQR1XS
KYSE-450	NFPSflBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHTkUW5KSzVyPUOuOlg2QDJizszN	MVjTRW5ITVJ?
KYSE-510	NVnPVZRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYm5WIxTUUN3ME2zMlczOThzIN88US=>	M33JRnNCVkeHUh?=
GP5d	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWqwW3ByUUN3ME2zMlczQTVizszN	M3fyVnNCVkeHUh?=
RPMI-7951	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlXUTWM2OD1\|Lke0O\|I{KM7:TR?=	NWjXXWlEW0GQR1XS
Becker	NUC3XItnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTNwN{WwNVIh\|ryP	M37pN3NCVkeHUh?=
WM-115	NWnjN4hoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHzrVIlKSzVyPUOuO\|gyQTVizszN	NUD6dmtYW0GQR1XS
G-401	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1r4cWlEPTB;Mz63PVA5PSEQvF2=	MVHTRW5ITVJ?
PANC-08-13	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXzxNXQ6UUN3ME2zMlc6PjB{IN88US=>	NIX4XndUSU6JRWK=
SW982	NHLBN3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnn3TWM2OD1\|LkiwOVUyKM7:TR?=	MYrTRW5ITVJ?
D-263MG	NH7yOVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnFepd7UUN3ME2zMlgzODVzIN88US=>	NFjBPXBUSU6JRWK=
KM-H2	NE\nWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWXJR\|UxRTNwOEK2NlQh\|ryP	Mm\IV2FPT0WU
SK-MEL-3	NWX0WoVET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXqbFVoUUN3ME2zMlgzQDRzIN88US=>	MoD5V2FPT0WU
NCI-H1581	NGq4V2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFixWXpKSzVyPUOuPFQ1QDhizszN	M2POUnNCVkeHUh?=
LS-123	M4rSNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrNdIZKSzVyPUOuPFc6ODlizszN	M1TLfnNCVkeHUh?=
CAKI-1	M4f6bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3nvU2lEPTB;Mz64PVA2OiEQvF2=	NWnH[HRjW0GQR1XS
MEL-JUSO	MmO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{LzOGlEPTB;Mz64PVE2OyEQvF2=	M2XKUHNCVkeHUh?=
HCE-4	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1myXGlEPTB;Mz65NVY3OyEQvF2=	MXTTRW5ITVJ?
TE-10	NFeyb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTNwOUKwNUDPxE1?	NYDSNVVlW0GQR1XS
OVCAR-4	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{DQRmlEPTB;Mz65Nlg5QSEQvF2=	MVPTRW5ITVJ?
ETK-1	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M324emlEPTB;Mz65OFY{PSEQvF2=	MmK4V2FPT0WU
A2780	NIDUdHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFW0TFRKSzVyPUSuNFU6PjZizszN	M3f6NXNCVkeHUh?=
LU-65	MlTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\5SGlEPTB;ND6wO\|Y{OyEQvF2=	NUWycZdsW0GQR1XS
BHY	NGjLR\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF\RdplKSzVyPUSuNVI1QTVizszN	NVe0XY9EW0GQR1XS
COR-L105	NW\iNG5zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTRwMUOwOVEh\|ryP	NVTYW\|BTW0GQR1XS
CAL-12T	M1G5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NW\kbIEzUUN3ME20MlE{OTB\|IN88US=>	NXTNRY5pW0GQR1XS
SCH	NEPDOoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1P5R2lEPTB;ND6xOVc1OyEQvF2=	NGj1eZBUSU6JRWK=
CW-2	MmnGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknQTWM2OD12LkG5NFAyKM7:TR?=	M3rSWXNCVkeHUh?=
HCC1806	NUHEOWx3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWS2XIRGUUN3ME20MlIxOzF{IN88US=>	NFXWRWVUSU6JRWK=
KP-N-YN	MlewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXPJR\|UxRTRwMkC5Nlch\|ryP	Mk\qV2FPT0WU
T98G	MlTlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlzFTWM2OD12LkKyNVU4KM7:TR?=	NIXtPW1USU6JRWK=
CAL-54	NY\vbFhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mln6TWM2OD12LkKyN\|gyKM7:TR?=	NWqyfmVKW0GQR1XS
CAL-33	MkjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnZTWM2OD12LkKzNFY1KM7:TR?=	MnGzV2FPT0WU
SNU-C2B	Mlv5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGTXSGhKSzVyPUSuNlQ4PjlizszN	NHLvZZJUSU6JRWK=
NUGC-3	NEW3RopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzsc3ZKSzVyPUSuNlU2ODVizszN	NH;ad21USU6JRWK=
DOK	NVz4fFVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\MR5d{UUN3ME20MlI3PTl\|IN88US=>	NU\jTWR6W0GQR1XS
MMAC-SF	NYXYd2pQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHyydXFKSzVyPUSuNlY5PTlizszN	MX;TRW5ITVJ?
KYSE-70	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVrJR\|UxRTRwMkmzOEDPxE1?	MUTTRW5ITVJ?
A204	M2\Idmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\XVWlEPTB;ND6zOVgxOyEQvF2=	MkPLV2FPT0WU
SCC-25	NGD4UHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHaTWM2OD12LkO1PFE6KM7:TR?=	Ml7TV2FPT0WU
EPLC-272H	MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvzTWM2OD12LkO4PVUh\|ryP	M173e3NCVkeHUh?=
CAL-120	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnGwTWM2OD12LkO4PVkzKM7:TR?=	NYqwR\|gxW0GQR1XS
LS-513	NX;PS2NHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjMRplKSzVyPUSuOFIyQThizszN	NYPBUWxGW0GQR1XS
CAPAN-1	NWPRZmFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUG3Z\|NbUUN3ME20MlQzOzh{IN88US=>	MWDTRW5ITVJ?
ESS-1	NHjJcWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGjvVINKSzVyPUSuOFI4OjRizszN	M17yV3NCVkeHUh?=
GMS-10	MmnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIX5VmZKSzVyPUSuOFI5OTlizszN	M2XL[XNCVkeHUh?=
NCI-N87	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NW\ve3N5UUN3ME20MlUxQDZ6IN88US=>	MVTTRW5ITVJ?
HMV-II	MnX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfscG1KSzVyPUSuOVE4OyEQvF2=	Ml;VV2FPT0WU
COLO-741	M1XIXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIrq[W1KSzVyPUSuOVU6QTRizszN	NFzIOXlUSU6JRWK=
MKN45	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml7UTWM2OD12LkW3O\|MzKM7:TR?=	NHzsfVdUSU6JRWK=
OAW-28	Mnz5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml7vTWM2OD12LkW4N\|k5KM7:TR?=	NVPUZVlFW0GQR1XS
OCI-AML2	MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVHM[5pYUUN3ME20MlY2OjN6IN88US=>	Mo\sV2FPT0WU
MDA-MB-231	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnG2TWM2OD12LkewNlQ{KM7:TR?=	NGryTo9USU6JRWK=
NCI-H1648	NILTSVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEnZeVFKSzVyPUSuO\|IzPzNizszN	MUjTRW5ITVJ?
NCI-H1792	NFTmUFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MojkTWM2OD12Lke2NVA4KM7:TR?=	MVLTRW5ITVJ?
GCIY	MnuwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlvtTWM2OD12Lke3OFI1KM7:TR?=	NXrBd2l{W0GQR1XS
Hs-578-T	Mn;uS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVHJR\|UxRTRwN{e2OVUh\|ryP	NFLSOIRUSU6JRWK=
SW962	Mk\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHH3fItKSzVyPUSuO\|gxOTFizszN	MUHTRW5ITVJ?
NCI-H630	NIX2WVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3H6SWlEPTB;ND63PFA5OSEQvF2=	NYPkS5Z7W0GQR1XS
786-0	NYnqV49LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2f2fWlEPTB;ND63PFc4OyEQvF2=	NIrTZZFUSU6JRWK=
FTC-133	NUSyc45CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV3JR\|UxRTRwN{myOlMh\|ryP	MkXKV2FPT0WU
BT-20	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\ieGlEPTB;ND63PVQzQSEQvF2=	NXPmfFJsW0GQR1XS
Mewo	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPzTWM2OD12LkixO\|Q4KM7:TR?=	M{PUOHNCVkeHUh?=
SW780	NHjFd3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHfxXGhKSzVyPUSuPFU4PjZizszN	M4D1W3NCVkeHUh?=
OE33	NHnPWI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjhd3V4UUN3ME20Mlg4PzF\|IN88US=>	MlntV2FPT0WU
HCC1569	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3y0OGlEPTB;ND64PFQ2QCEQvF2=	M{T5TXNCVkeHUh?=
TE-6	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlL1TWM2OD12LkmzPVc4KM7:TR?=	NE\POGtUSU6JRWK=
SK-N-FI	NYToSFdzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkW2TWM2OD12Lkm0OFIyKM7:TR?=	Mk\SV2FPT0WU
PANC-03-27	M32xTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTRwOUm5OlIh\|ryP	M36ye3NCVkeHUh?=
MCF7	NXPIUlJET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml61TWM2OD13LkCwO\|M5KM7:TR?=	M1TJWXNCVkeHUh?=
UACC-257	MoTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mof4TWM2OD13LkCyPFQ2KM7:TR?=	NEWzTYtUSU6JRWK=
SW1088	NG[xSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkDtTWM2OD13LkCyPVQ1KM7:TR?=	MVXTRW5ITVJ?
A704	NXnGUFloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUGzTplQUUN3ME21MlA{ODZizszN	MVzTRW5ITVJ?
A2058	NEXKUHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFrMdVJKSzVyPUWuNFU6ODhizszN	NHfjbWdUSU6JRWK=
Calu-3	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzPRZNKSzVyPUWuNFY1PTJizszN	NICwWWxUSU6JRWK=
RERF-LC-MS	MoO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFG2elRKSzVyPUWuNFY6ODNizszN	Mnn2V2FPT0WU
AU565	NX;6RZpVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\rbmlEPTB;NT6wPVcxOiEQvF2=	NUXRO4NWW0GQR1XS
DMS-79	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnf6TWM2OD13LkGzPFg{KM7:TR?=	NHHCPG1USU6JRWK=
DK-MG	NVzifGxtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoT6TWM2OD13LkG4OFM5KM7:TR?=	NVO3O2hJW0GQR1XS
HuCCT1	M1n0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTVwMkO4OVYh\|ryP	MlLsV2FPT0WU
HT-144	M4C0RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTVwMkS5PFch\|ryP	M{G4SnNCVkeHUh?=
M059J	M4n0bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXv1WlB[UUN3ME21MlI2PzZizszN	NX3tbphHW0GQR1XS
COLO-792	NHqzUGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1HqWmlEPTB;NT6yOlM2PiEQvF2=	NYPiRlR4W0GQR1XS
SF539	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmiyTWM2OD13LkK2OlMzKM7:TR?=	NYq0bI9HW0GQR1XS
SK-UT-1	NIDRXYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTVwMke3OVEh\|ryP	NWT0cGUyW0GQR1XS
NCI-H1703	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYq5cFA4UUN3ME21MlM2QDJ4IN88US=>	MmHJV2FPT0WU
SW837	M1u2S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\jeGlEPTB;NT6zO\|g4QCEQvF2=	MVTTRW5ITVJ?
U251	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF[3VItKSzVyPUWuN\|kxQTZizszN	M4ezbHNCVkeHUh?=
SW1710	NGT0ZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHLHfFhKSzVyPUWuOFE2PTRizszN	M2S5OXNCVkeHUh?=
NCI-H1299	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWDJR\|UxRTVwNE[zN\|Uh\|ryP	M{TpZXNCVkeHUh?=
RVH-421	NFzFb4pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYDRV491UUN3ME21MlQ6QTB6IN88US=>	NGG3WnNUSU6JRWK=
UM-UC-3	M3HjO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2fDVGlEPTB;NT62NlY2OSEQvF2=	NUD0enRIW0GQR1XS
MDA-MB-175-VII	M1L3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1r1d2lEPTB;NT62OFA1OSEQvF2=	MojuV2FPT0WU
KYSE-270	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFm5fJRKSzVyPUWuOlYxOzFizszN	Mmj5V2FPT0WU
COLO-668	NUSxXpJqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzufGhWUUN3ME21MlcyOzJizszN	NFL2VHNUSU6JRWK=
LN-405	MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTVwN{OwPFUh\|ryP	NGW0e4tUSU6JRWK=
HT-1376	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{fsV2lEPTB;NT63PFA2OiEQvF2=	M1PDSXNCVkeHUh?=
769-P	M2PRTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzKT3VKSzVyPUWuPFY4OThizszN	NH;RfVJUSU6JRWK=
HuP-T3	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGOwOm1KSzVyPUWuPFg3PzdizszN	M{\iWHNCVkeHUh?=
MDA-MB-415	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HOXmlEPTB;NT65NlE{QSEQvF2=	Mln3V2FPT0WU
MKN7	NH3sTo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LDT2lEPTB;NT65PFgh\|ryP	NGfiNHZUSU6JRWK=
KS-1	M1nqS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYHLTlFsUUN3ME21Mlk5QDN4IN88US=>	MkPhV2FPT0WU
647-V	M{DMb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEXoTWhKSzVyPUWuPVkyPDhizszN	MoPXV2FPT0WU
COLO-679	M1Oybmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTuTWM2OD14LkCwNlU2KM7:TR?=	MWDTRW5ITVJ?
AN3-CA	M3nFNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTZwMEO0OFEh\|ryP	M{LjVHNCVkeHUh?=
C32	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnW5TWM2OD14LkGzNFM1KM7:TR?=	MUHTRW5ITVJ?
KM12	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmHlTWM2OD14LkK0NFk6KM7:TR?=	NXLaSGV[W0GQR1XS
KINGS-1	NX7oZpZTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmK4TWM2OD14LkK2NVUzKM7:TR?=	MnvRV2FPT0WU
KYSE-410	MorLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDlTWM2OD14LkOwOlQ2KM7:TR?=	M4\5UHNCVkeHUh?=
HPAF-II	NIDYcnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXGWmNKSzVyPU[uN\|U1QCEQvF2=	MlziV2FPT0WU
LAN-6	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fKTGlEPTB;Nj60PVY{OSEQvF2=	MWDTRW5ITVJ?
LU-99A	Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7mdGg5UUN3ME22MlU2QTh7IN88US=>	NH71d3VUSU6JRWK=
SJSA-1	NVPpXlR7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXnUN5VkUUN3ME22MlU3OzR5IN88US=>	NF\jb2VUSU6JRWK=
MSTO-211H	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXCeG1oUUN3ME22MlczOjN\|IN88US=>	Mn\CV2FPT0WU
SW900	NVvhdohjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETRXZJKSzVyPU[uO\|YzOjFizszN	Mli4V2FPT0WU
LNCaP-Clone-FGC	NH\2UFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHWzbo5KSzVyPU[uPFA1ODNizszN	Mke5V2FPT0WU
OMC-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PEWWlEPTB;Nj64OVQxOiEQvF2=	MmLwV2FPT0WU
IST-MEL1	NWLqcFFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVy5O4I4UUN3ME22Mlg6PjZ7IN88US=>	M17BcXNCVkeHUh?=
TE-9	NEHiNI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoCzTWM2OD14Lki5PFQ4KM7:TR?=	M2TCV3NCVkeHUh?=
NCI-H2030	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4C4W2lEPTB;Nj65NVIzPiEQvF2=	NUnZOlRoW0GQR1XS
BFTC-909	NFrGUYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml7ITWM2OD15LkCwOlQyKM7:TR?=	NG\Ocm9USU6JRWK=
NCI-SNU-5	MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTdwMEKxOVkh\|ryP	NEm5Nm9USU6JRWK=
TE-5	M3zKeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGi4Nm9KSzVyPUeuNFI5QDFizszN	MVrTRW5ITVJ?
SK-MES-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MV;JR\|UxRTdwMEW0Nlch\|ryP	MoXpV2FPT0WU
SHP-77	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkP0TWM2OD15LkGzPVUzKM7:TR?=	MnfVV2FPT0WU
NCI-H1623	M3W3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLRUZRKSzVyPUeuNVQxPzJizszN	NVrPdGlRW0GQR1XS
TE-11	NIDI[phIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILFNGRKSzVyPUeuNVUyQDRizszN	NFX2UHFUSU6JRWK=
EKVX	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\pUZJCUUN3ME23MlE6OjZ5IN88US=>	MV\TRW5ITVJ?
OVCAR-3	MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHjHXXRKSzVyPUeuNlEyOzNizszN	M{n5S3NCVkeHUh?=
C3A	NVPDSFZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rXbmlEPTB;Nz6zOFUzKM7:TR?=	NHi3RZJUSU6JRWK=
CFPAC-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;YWWlEPTB;Nz6zOlIzOiEQvF2=	MofwV2FPT0WU
MG-63	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTdwNEG4OFkh\|ryP	M176cHNCVkeHUh?=
KYSE-140	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4PldGlEPTB;Nz60OFA3OSEQvF2=	M{PXWHNCVkeHUh?=
MPP-89	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH;vZohKSzVyPUeuOVk4OjlizszN	NX7mdWM2W0GQR1XS
COLO-824	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoiyTWM2OD15LkeyPFY{KM7:TR?=	NIfLd3lUSU6JRWK=
SiHa	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M33KdWlEPTB;Nz64N\|cxPyEQvF2=	M{PuRnNCVkeHUh?=
SNU-387	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYHSZ3N{UUN3ME23Mlg2OzR5IN88US=>	M1vMR3NCVkeHUh?=
A172	MoLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYXJR\|UxRTdwOE[xO\|Ih\|ryP	NYi0V2NCW0GQR1XS
COLO-680N	Mn7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M17TOmlEPTB;Nz65NVc{KM7:TR?=	NFjpN2lUSU6JRWK=
HCC1395	NFHMWIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVTJR\|UxRThwMEW0OVIh\|ryP	MnLIV2FPT0WU
NCI-H28	NXLSW4VHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWDJR\|UxRThwMEW5OlMh\|ryP	MWXTRW5ITVJ?
LC-2-ad	Ml7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX:zfY9mUUN3ME24MlIyQTN5IN88US=>	NU\HTYNyW0GQR1XS
S-117	NYrPcWNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWTJR\|UxRThwMkWzOVMh\|ryP	MWXTRW5ITVJ?
NCI-H1838	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoPOTWM2OD16LkK1O\|gyKM7:TR?=	MlLsV2FPT0WU
PANC-10-05	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrjcnVKSzVyPUiuN\|cxPDdizszN	NWW4SYFiW0GQR1XS
KALS-1	M3v3PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXBTWM2OD16LkWwPVI5KM7:TR?=	MlPZV2FPT0WU
LS-1034	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFraToxKSzVyPUiuOVc1OzdizszN	M{TBXXNCVkeHUh?=
TGBC1TKB	Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvlPZQ4UUN3ME24Mlc{PTN3IN88US=>	M1XvNHNCVkeHUh?=
OE19	NIPrZYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRThwN{[yOlIh\|ryP	Ml\RV2FPT0WU
D-502MG	MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnP[oVKSzVyPUiuO\|Y6QTRizszN	M4O5WXNCVkeHUh?=
JEG-3	NIT4T4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXXJR\|UxRThwN{i2NVgh\|ryP	MVPTRW5ITVJ?
DBTRG-05MG	NX7jV5JbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2SwUmlEPTB;OD64O\|U3PSEQvF2=	MkfFV2FPT0WU
ME-180	MmXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUjJR\|UxRTlwME[3NlUh\|ryP	NXfYVoZiW0GQR1XS
NCI-H1573	MkHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX;mXGZRUUN3ME25MlExPTN{IN88US=>	Mm\IV2FPT0WU
HCC2998	MlfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTlwMUO2PFEh\|ryP	MXvTRW5ITVJ?
ACHN	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2HjZ2lEPTB;OT6yOFk4PSEQvF2=	NVjKSllGW0GQR1XS
D-392MG	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17HS2lEPTB;OT6yOVcyPSEQvF2=	MmDRV2FPT0WU
no-11	NG\UNpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NILEUotKSzVyPUmuNlYxOjhizszN	M3HafnNCVkeHUh?=
KLE	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlfPTWM2OD17LkOyNlMzKM7:TR?=	MXvTRW5ITVJ?
Calu-6	MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M334TWlEPTB;OT6zO\|UzQCEQvF2=	MlHrV2FPT0WU
LB831-BLC	NU[2XZdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGH6[W1KSzVyPUmuOFUyPzFizszN	MWrTRW5ITVJ?
SW684	NFn1eZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYLJR\|UxRTlwNE[xNVYh\|ryP	M{nBTnNCVkeHUh?=
SH-4	Mkj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYf2U2RxUUN3ME25MlQ6OzZ2IN88US=>	M{XPXnNCVkeHUh?=
IST-MES1	M3jnXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUS1WmF5UUN3ME25MlUyPjR2IN88US=>	NWP6N5U3W0GQR1XS
Saos-2	MlvrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV6xbGRtUUN3ME25MlUzOTl3IN88US=>	M3jZe3NCVkeHUh?=
NCI-H2087	MnzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvNTVV[UUN3ME25MlY4OzV{IN88US=>	MnL3V2FPT0WU
SCC-9	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MniyTWM2OD17LkexPFE3KM7:TR?=	M1v4fnNCVkeHUh?=
MFE-280	Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTlwN{K3PFUh\|ryP	MkHwV2FPT0WU
BEN	Mmj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjWTpZyUUN3ME25MlgzOTV7IN88US=>	NF;EfWVUSU6JRWK=
CP50-MEL-B	NXjJO\|dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTMR45KSzVyPUmuPVI1OzJizszN	NULUe2JXW0GQR1XS
SK-MEL-28	NGDsR\|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mmm5TWM2OD1zMD6wNVk{KM7:TR?=	NWnFPHhVW0GQR1XS
NCI-H2452	Ml6xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTUeIJKSzVyPUGwMlE3KM7:TR?=	MVXTRW5ITVJ?
NCI-H1395	MnL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWT5Z4JKUUN3ME2xNE4yPzhizszN	MWHTRW5ITVJ?
NCI-H2052	MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1vKemlEPTB;MUCuNVg5OiEQvF2=	NUDnWFF[W0GQR1XS
A375	NHvIdpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{Tq[mlEPTB;MUCuNlQ2OiEQvF2=	NV;DSmVkW0GQR1XS
HCC38	M37LXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVfJR\|UxRTFyLkOyNkDPxE1?	NXLZeZFPW0GQR1XS
LK-2	Mnj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mk\nTWM2OD1zMD60NlA5KM7:TR?=	NFO0OWNUSU6JRWK=
SF126	NInCWVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIjyU3RKSzVyPUGwMlQ4OjdizszN	MUnTRW5ITVJ?
SK-MEL-1	NV;LVVJ4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofNTWM2OD1zMD63PFM5KM7:TR?=	Ml;iV2FPT0WU
ACN	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\K[Yc{UUN3ME2xNE45Pjd7IN88US=>	NID1T4xUSU6JRWK=
BB30-HNC	MofqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3z1NWlEPTB;MUCuPFcyOSEQvF2=	M4D0WXNCVkeHUh?=
NCI-H747	NYO1WZh7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPvdoZ1UUN3ME2xNE45PzR4IN88US=>	MmL6V2FPT0WU
KYSE-150	MkDUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rBOmlEPTB;MUGuNFM5PyEQvF2=	MojsV2FPT0WU
D-247MG	NXzXRlczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDWW4tKSzVyPUGxMlExODlizszN	NF3qSm5USU6JRWK=
BxPC-3	MnjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXfN[GpXUUN3ME2xNU4{PzR5IN88US=>	NVf4dG5bW0GQR1XS
SK-MEL-30	MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTFzLkSwO\|kh\|ryP	NWS3SWJ1W0GQR1XS
CAS-1	NY\TWYpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWfNW3RXUUN3ME2xNU41OTB7IN88US=>	MXjTRW5ITVJ?
no-10	NV7UToo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M37tbmlEPTB;MUKuNVIyPyEQvF2=	Mn7RV2FPT0WU
NCI-H2405	M2XMW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLzR25KSzVyPUGyMlIxOzZizszN	NG\IPZRUSU6JRWK=
KGN	NH22SZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmHsTWM2OD1zMj6yPVAyKM7:TR?=	Mk\iV2FPT0WU
BB49-HNC	M4CyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnvzTWM2OD1zMj6zPVU3KM7:TR?=	NEXjV5hUSU6JRWK=
NCI-H1693	M4DW[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVvJR\|UxRTF{LkW4NVYh\|ryP	M{PXVXNCVkeHUh?=
RO82-W-1	NWHvd4c5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFzQNphKSzVyPUGzMlA3PDlizszN	NYHqe3BDW0GQR1XS
CAL-85-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVfzR5UzUUN3ME2xN{41Ozl7IN88US=>	M2PTcHNCVkeHUh?=
H-EMC-SS	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVnJR\|UxRTF\|LkmxNFQh\|ryP	NWCyWndUW0GQR1XS
SW1783	M{Hwfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fWWGlEPTB;MUSuNlM6OSEQvF2=	MUnTRW5ITVJ?
LB771-HNC	M{GyWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX70PVdLUUN3ME2xOE41OTlizszN	Mn2zV2FPT0WU
HCC70	M3\B[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTF2LkSyN\|Mh\|ryP	M3f6NXNCVkeHUh?=
KNS-81-FD	M1nSO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV3JR\|UxRTF2LkewOFUh\|ryP	MWDTRW5ITVJ?
KYSE-520	NXXVNJU4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXY[GI6UUN3ME2xOE46OjdizszN	M3;pSXNCVkeHUh?=
TGBC24TKB	MlG1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYS1clVjUUN3ME2xOE46PTN7IN88US=>	NFTY[VRUSU6JRWK=
SNB75	NEixW3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWrGXYFJUUN3ME2xOU4xPzJ7IN88US=>	MXrTRW5ITVJ?
SW872	MlXnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzIfoZbUUN3ME2xOU4zOjF6IN88US=>	MVTTRW5ITVJ?
U031	NY\UeXF1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWnJR\|UxRTF3LkiwNlgh\|ryP	MX7TRW5ITVJ?
ChaGo-K-1	M2TCbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXjJR\|UxRTF3LkizOVkh\|ryP	MlTrV2FPT0WU
NCI-H441	NYfLZVZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvhXJRkUUN3ME2xOk4xODN7IN88US=>	Mn7VV2FPT0WU
TE-12	M4LucWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXLJR\|UxRTF4LkG4O\|Mh\|ryP	NVvEc3lmW0GQR1XS
NCI-H1755	NHL3PFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmjITWM2OD1zNj61O\|Mh\|ryP	NV;lXo9oW0GQR1XS
KNS-42	NYnYdYIzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo\kTWM2OD1zNj62OVg6KM7:TR?=	MWPTRW5ITVJ?
SK-PN-DW	MmDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvrUGhKSzVyPUG3MlQzODFizszN	MoO2V2FPT0WU
NCI-H226	NHWwcG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4f6[WlEPTB;MUeuPVM1PSEQvF2=	NGjybHlUSU6JRWK=
K-562	NYLzfWN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTF6Lk[zNVch\|ryP	NXHiSHBQW0GQR1XS
A388	MkGzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnS4TWM2OD1zOT6wN\|A{KM7:TR?=	NX7BWFlVW0GQR1XS
ZR-75-30	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4ewPGlEPTB;MUmuNFk3QCEQvF2=	NVjJd4c6W0GQR1XS
LU-135	MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVrJR\|UxRTF7LkK2N\|Yh\|ryP	NFTxe2lUSU6JRWK=
NCI-H2029	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXLMdphNUUN3ME2xPU43ODJzIN88US=>	NVr1[5M{W0GQR1XS
HT-1197	NWDie3JVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTF7LkmyNlch\|ryP	M1LVXnNCVkeHUh?=
IGR-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTJyLkOxNVch\|ryP	MnL6V2FPT0WU
U-87-MG	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NInqW\|dKSzVyPUKwMlY1OTNizszN	MWTTRW5ITVJ?
NCI-H1304	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\4Z4xKSzVyPUKwMlc2ODFizszN	MkXGV2FPT0WU
RCC10RGB	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTJzLkK4Nlkh\|ryP	NWnYWHF4W0GQR1XS
NCI-H520	M4TxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTJ{Lke2NVEh\|ryP	NGjJeWRUSU6JRWK=
SK-LU-1	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHrTWM2OD1{Mz6wO\|E5KM7:TR?=	M1LGU3NCVkeHUh?=
UACC-893	NEiw[GJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml;4TWM2OD1{Mz6xNFM5KM7:TR?=	NHHEPVJUSU6JRWK=
NCI-H2347	M{Prfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFjBVHpKSzVyPUKzMlI3PzRizszN	M4jyZXNCVkeHUh?=
U-118-MG	NXjLTWU1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTETWM2OD1{Mz63NlE4KM7:TR?=	MnLaV2FPT0WU
NCI-H596	M4HTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4T6WmlEPTB;MkOuPVA2PSEQvF2=	NGLmNnVUSU6JRWK=
MZ1-PC	M2jGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVTJR\|UxRTJ2Lk[3OVkh\|ryP	M3noOHNCVkeHUh?=
SW1417	MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPmTWM2OD1{NT6yOFk5KM7:TR?=	NHq2U4FUSU6JRWK=
NCI-H82	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVP6bmhMUUN3ME2yOk41Ojh6IN88US=>	MlKyV2FPT0WU
COLO-678	NVGwOYk{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M33MRWlEPTB;MkeuOFkyQSEQvF2=	NVf1UHdjW0GQR1XS
KURAMOCHI	M1rSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLmTWM2OD1{OD6xNlYh\|ryP	NF;TfphUSU6JRWK=
NCI-H1650	MnfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlfrTWM2OD1\|MD6xPVI1KM7:TR?=	NW[ySY9KW0GQR1XS
HCC1954	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEL1TINKSzVyPUOxMlM3PjZizszN	NFvhT4JUSU6JRWK=
GAK	MnzES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnPwTWM2OD1\|Mj6yOlE3KM7:TR?=	MUfTRW5ITVJ?
YAPC	NF3UNoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTN\|Lke2OFgh\|ryP	M3XsNnNCVkeHUh?=
NCI-H2228	NWHlboJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTN2LkO2NFUh\|ryP	MYHTRW5ITVJ?
VMRC-RCZ	M3nHbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV\IcHZ7UUN3ME2zOk4{ODJ{IN88US=>	NFLYT\|BUSU6JRWK=
NMC-G1	M{HtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWrJR\|UxRTN5LkC1Nlkh\|ryP	NFHqfo1USU6JRWK=
D-336MG	NUjacHVzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1O3dWlEPTB;NEGuPFQ1OiEQvF2=	MY\TRW5ITVJ?
UACC-62	NWD5[HZPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUTJR\|UxRTR{LkW1NFUh\|ryP	MnXRV2FPT0WU
C-33-A	NVTCXoR3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoPkTWM2OD12NT6zNlU3KM7:TR?=	MWfTRW5ITVJ?
HCC1937	MkfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLrdXBKSzVyPUS3MlE6PThizszN	M3;SXHNCVkeHUh?=
HDLM-2	NYPtU3dGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrwXFNKSzVyPUS3MlIzQDdizszN	NVnOZ3JjW0GQR1XS
NCI-H727	M1r6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjXcYJKSzVyPUS3MlI1PTFizszN	NE\hW3dUSU6JRWK=
NY	NEn2XFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MULJR\|UxRTR7LkO5NFgh\|ryP	NGXROmhUSU6JRWK=
NCI-H2291	NF;xPI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoTSTWM2OD12OT64N\|AyKM7:TR?=	NEnKWIFUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Ac-Histone H4 / Ac-Histone H3; PubMed: 21598070 J Neurooncol D54 and U87 glioma cells were treated with lower concentrations (1-3 µM) of vorinostat. The effects on histone acetylation was assessed by immunoblotting. phospho-CDK1; PubMed: 21598070 Changes in level of inhibitory phosphorylation of cdk1 after treatment with vorinostat was determined at 24 and 48 h (using a Tyr-15 residue phospho-specific antibody) along with total cdk1 as loading control. phospho-Cdc25c / Cdc25c; PubMed: 21598070 J Neurooncol Time course of changes in phospho-cdc25c levels after exposure to vorinostat (5 µM). Cyclin B1; PubMed: 21598070 J Neurooncol Cyclin B1 levels were determined in D54 and U87 cells after treatment with various doses of vorinostat at 24 and 48 h. c-Myc / c-Raf / Akt / Cyclin D1 / CDK4; PubMed: 19440035 Cancer Biol Ther Cell lysates from JeKo-1 and Mo2058 cells exposed to vorinostat were immunoblotted for c-Myc, c-Raf, AKT, cyclin D1, CDK4 and acetylated histone H3. The levels of β-actin served as the loading control. p-eIF2α / ATF4 / CHOP ; PubMed: 20072656 Neoplasia Western blot was performed to evaluate activated eIF2α (P-eIF2α), translational up-regulation of ATF4, and CHOP expression in U251 cells after vorinostat exposure. p21; PubMed: 21598070 J Neurooncol To determine the dose response relationship to vorinostat, cells were exposed to various higher concentrations (5–10 µM) of the agent and the levels of p21 determined by immunoblotting.	21598070 19440035 20072656
Immunofluorescence	HDAC1 / CK19; PubMed: 29917299 Cancer Sci Immunocytochemistry to detect the expression of HDAC1 and CK 19 in PDAC cells with/without Vorinostat treatment. HDAC1 and CK19 were stained red and green, respectively. The Hoechst‐stained nuclei appear blue. Scale bar: 100 μm. The CK19 expression in PSN1 and MiaPaCa2 was increased by Vorinostat treatment. Nrf2; PubMed: 20566897 Blood Vorinostat induced translocation of Nrf2 from cytosol to nucleus. U937 cells were treated with 2μM vorinostat for 18 hours and then cytospun. Cells were fixed and labeled for Nrf2 protein (red) and nucleus (blue, 4,6-diamidino-2-phenylindole) as described in “Immunofluorescence and confocal microscopy.” Images were taken by Nikon Eclipse TE2000 confocal microscope with 40×/1.30 numeric aperture oil objective lens. Ctrl indicates control cells without treatment; and Vor, vorinostat. α-SMA; PubMed: 26330748 Mol Vis Representative immunofluorescence images and the quantification graph showing the effect of vorinostat (2.5 µM), TGIF1, and TGIF2 siRNA knockdown on αSMA. Control human corneal fibroblast cultures (-TGFβ) showed no αSMA staining. Cultures treated with TGFβ1 (5 ng/ml) showed a robust αSMA staining. Vorinostat treatment markedly attenuated TGFβ-evoked αSMA staining. The knockdown of TGIF1 (+TGFβ+vorinostat+TGIF1siRNA) and TGIF2 alone (+TGFβ+vorinostat+TGIF2siRNA) or in combination (+TGFβ +vorinostat +TGIF1 +2siRNA) markedly blocked the effect of vorinostat on αSMA. Scale bar=100 μm. Ac-STAT3 / IGF2; PubMed: 27086926 Oncogene Immunofluorescence staining of Ac-STAT3 and IGF2 after vorinostat treatment.	29917299 20566897 26330748 27086926
Growth inhibition assay	Cell apoptosis; PubMed: 19440035 Cancer Biol Ther Cells were treated with indicated concentrations of vorinostat for 48 hours. Following this, the percentage of annexin-V-stained apoptotic cells was determined by flow cytometry. Values represented as bar graphs are the mean of 3 experiments plus or minus the standard error (SE) Cell viability; PubMed: 27086926 Oncogene The effects of vorinostat on the viability of the indicated NSCLC cell lines and their corresponding acquired VoR sublines. Cell viability was determined by the MTT assay (n = 3).	19440035 27086926
ELISA	IGF2; PubMed: 27086926 Oncogene Determination of vorinostat-induced IGF2 production by ELISA (n = 3). The conditioned mediums (CMs) obtained from cells treated with vorinostat (5 μM) for 2 days were used for ELISA. IL-13 / IL-10 / IL-5; PubMed: 18541724 Blood Effect of vorinostat on TH1/TH2 cytokine secretion in HL cell lines. Cells were incubated with medium or vorinostat (5 μM) for 24 hours and supernatants were examined for cytokine levels by ELISA. Each value represents a mean of 3 independent experiments done in triplicate (± SEM). M-CSF; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for M-CSF secretion. P < 0.05 and P < 0.001 versus control treatment. MMP-9; PubMed: 23042302 Carcinogenesis Primary PyMT tumor cells were treated with SAHA (0-1000nM) for varying time points (8–48h), and supernatants were assayed by ELISA for MMP-9 secretion. P < 0.05 and **P < 0.001 versus control treatment.	27086926 18541724 23042302

In vivo

Administration of Vorinostat (~100 mg/kg/day) significantly inhibits the growth of CWR22 human prostate xenografts in nude mice with tumor reductions of 78%, 97% and 97%, at doses of 25 mg/kg/day, 50 mg/kg/day and 100 mg/kg/day, respectively, compared with control. Vorinostat induces the accumulation of acetylated core histones and prostate-specific antigen mRNA expression in CWR22 cells, resulting in higher levels of serum prostate-specific antigen than predicted from tumor volume alone. ^[2] Oral administration of Vorinostat (0.67g/L) crosses the blood-brain barrier, increases histone acetylation in the brain, and dramatically improves the motor impairment in the R6/2 mice model of Huntington's disease. ^[5]

Protocol

Kinase Assay: ^[1]	+ Expand Immunoprecipitation-HDAC assays: The lysate of Jurkat cells is incubated for 1 hour on ice and cleared by centrifugation at 12,000 g for 10 minutes at 4 °C. Supernatants are precleared with 30 μL of 50% protein G-Sepharose slurry for 1 hour at 4 °C. Beads are pelleted by centrifugation and supernatants are incubated for 1 hour at 4 °C with 10 μg of IgG fraction from anti-HDAC1 or HDAC3 polyclonal antisera (preincubated 2 hours at room temperature with either the homologous or heterologous immunizing peptide). Both antisera are raised in rabbits against the carboxylterminal peptide of HDAC1 and HDAC3 by using synthetic peptides coupled to keyhole limpet hemocyanin. 30 μL of 50% protein G-Sepharose slurry is added for 1 hour at 4 °C. Immune complexes are pelleted by centrifugation and washed three times with 1 mL of lysis buffer. Beads are resuspended in 200 μL of HDAC buffer (20 mM Tris-HCl, pH 8.0/150 mM NaCl/10% glycerol), and the HDAC assay is performed with an ³H-acetylated peptide corresponding to amino acids 1-24 of histone H4. Released [³H]acetic acid is quantified by scintillation counting. For inhibitions studies, the immunoprecipitated complexes are preincubated with the different concentrations of Vorinostat for 30 minutes at 4 °C.
Cell Research: ^[2]	+ Expand Cell lines: LNCaP, PC-3, and TSU-Pr1 Concentrations: Dissolved in DMSO, final concentrations ~7.5 μM Incubation Time: 1, 2, 3 and 4 days Method: Cells are exposed to various concentrations of Vorinostat for 1, 2, 3 and 4 days. Cell viability is assessed by trypan blue dye exclusion. (Only for Reference)
Animal Research: ^[2]	+ Expand Animal Models: Male BALB/c nude (nu/nu) mice implanted with CWR22 tumor cells Formulation: Dissolved in DMSO Dosages: ~100 mg/kg/day Administration: Injection i.p. (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	52 mg/mL (196.74 mM)
	Ethanol	3 mg/mL (11.35 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Molecular Weight	264.3
Formula	C₁₄H₂₀N₂O₃
CAS No.	149647-78-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	SAHA, MK0683, suberoylanilide hydroxamic acid

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03022565	Suspended	Drug: Vorinostat	Uveal Melanoma	University of Miami\|University of Miami Sylvester Comprehensive Cancer Center	January 2020	Early Phase 1
NCT03167437	Recruiting	Drug: Vorinostat	Crohn''s Disease	National Institute of Allergy and Infectious Diseases (NIAID)\|National Institutes of Health Clinical Center (CC)	October 30 2017	Phase 1\|Phase 2
NCT03056495	Recruiting	Drug: N-hydroxy-N''-phenyl-octanediamide (Vorinostat)	Alzheimer Disease	German Center for Neurodegenerative Diseases (DZNE)\|University Hospital Bonn\|University of Göttingen	September 28 2017	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
What’s the recommendation about reconstitution of the compound for in vivo animal study?
Answer:
We recommend the following vehicle for S1047: 2% DMSO, 40% PEG 300, 5% Propylene glycol, 1% Tween 80 at 5 mg/mL.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA against cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Panobinostat (LBH589)

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 182 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Choose Your Country or Region

By Signaling Pathways

By product type

Vorinostat (SAHA, MK0683)

Cited by 182 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Vorinostat (SAHA, MK0683) SDF

Bio Calculators

Molarity Calculator

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

Frequently Asked Questions

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)